Hepatitis C virus inhibitors

ABSTRACT

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: 
                         
which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/351,327 filed on Jun. 4, 2010, U.S. Provisional Application No. 61/415,447 filed on Nov. 19, 2010 and U.S. Provisional Application No. 61/451,769 filed on Mar. 11, 2011. The entire teachings of each of the above applications are incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to novel antiviral agents. More specifically, the present invention relates to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C Virus (HCV), compositions comprising such compounds, methods for inhibiting HCV viral replication, methods for treating or preventing HCV infection, and processes for making the compounds.

BACKGROUND OF THE INVENTION

Infection with HCV is a major cause of human liver disease throughout the world. In the U.S., an estimated 4.5 million Americans are chronically infected with HCV. Although only 30% of acute infections are symptomatic, greater than 85% of infected individuals develop chronic, persistent infection. Treatment costs for HCV infection have been estimated at $5.46 billion for the US in 1997. Worldwide over 200 million people are estimated to be infected chronically. HCV infection is responsible for 40-60% of all chronic liver disease and 30% of all liver transplants. Chronic HCV infection accounts for 30% of all cirrhosis, end-stage liver disease, and liver cancer in the U.S. The CDC estimates that the number of deaths due to HCV will minimally increase to 38,000/year by the year 2010.

Due to the high degree of variability in the viral surface antigens, existence of multiple viral genotypes, and demonstrated specificity of immunity, the development of a successful vaccine in the near future is unlikely. Alpha-interferon (alone or in combination with ribavirin) has been widely used since its approval for treatment of chronic HCV infection. However, adverse side effects are commonly associated with this treatment: flu-like symptoms, leukopenia, thrombocytopenia, depression from interferon, as well as anemia induced by ribavirin (Lindsay, K. L. (1997) Hepatology 26 (suppl 1): 71S-77S). This therapy remains less effective against infections caused by HCV genotype 1 (which constitutes ˜75% of all HCV infections in the developed markets) compared to infections caused by the other 5 major HCV genotypes. Unfortunately, only ˜50-80% of the patients respond to this treatment (measured by a reduction in serum HCV RNA levels and normalization of liver enzymes) and, of responders, 50-70% relapse within 6 months of cessation of treatment. Recently, with the introduction of pegylated interferon (Peg-IFN), both initial and sustained response rates have improved substantially, and combination treatment of Peg-IFN with ribavirin constitutes the gold standard for therapy. However, the side effects associated with combination therapy and the impaired response in patients with genotype 1 present opportunities for improvement in the management of this disease.

First identified by molecular cloning in 1989 (Choo, Q-L et al (1989) Science 244:359-362), HCV is now widely accepted as the most common causative agent of post-transfusion non-A, non-B hepatitis (NANBH) (Kuo, G et al (1989) Science 244:362-364). Due to its genome structure and sequence homology, this virus was assigned as a new genus in the Flaviviridae family. Like the other members of the Flaviviridae, such as flaviviruses (e.g. yellow fever virus and Dengue virus types 1-4) and pestiviruses (e.g. bovine viral diarrhea virus, border disease virus, and classic swine fever virus) (Choo, Q-L et al (1989) Science 244:359-362; Miller, R. H. and R. H. Purcell (1990) Proc. Natl. Acad. Sci. USA 87:2057-2061), HCV is an enveloped virus containing a single strand RNA molecule of positive polarity. The HCV genome is approximately 9.6 kilobases (kb) with a long, highly conserved, noncapped 5′ nontranslated region (NTR) of approximately 340 bases which functions as an internal ribosome entry site (IRES) (Wang C Y et al ‘An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the Hepatitis C Virus 5’ noncoding region RNA—A Publication of the RNA Society. 1(5): 526-537, 1995 July). This element is followed by a region which encodes a single long open reading frame (ORF) encoding a polypeptide of ˜3000 amino acids comprising both the structural and nonstructural viral proteins.

Upon entry into the cytoplasm of the cell, this RNA is directly translated into a polypeptide of ˜3000 amino acids comprising both the structural and nonstructural viral proteins. This large polypeptide is subsequently processed into the individual structural and nonstructural proteins by a combination of host and virally-encoded proteinases (Rice, C. M. (1996) in B. N. Fields, D. M. Knipe and P. M. Howley (eds) Virology 2^(nd) Edition, p 931-960; Raven Press, N.Y.). There are three structural proteins, C, E1 and E2. The P7 protein is of unknown function and is comprised of a highly variable sequence. There are several nonstructural proteins. NS2 is a zinc-dependent metalloproteinase that functions in conjunction with a portion of the NS3 protein. NS3 incorporates two catalytic functions (separate from its association with NS2): a serine protease at the N-terminal end, which requires NS4A as a cofactor, and an ATP-ase-dependent helicase function at the carboxyl terminus. NS4A is a tightly associated but non-covalent cofactor of the serine protease. NS5A is a membrane-anchored phosphoprotein that is observed in basally phosphorylated (56 kDa) and hyperphosphorylated (58 kDa) forms. While its function has not fully been elucidated, NS5A is believed to be important in viral replication. The NS5B protein (591 amino acids, 65 kDa) of HCV (Behrens, S. E. et al. (1996) EMBO J. 151 2-22) encodes an RNA-dependent RNA polymerase (RdRp) activity and contains canonical motifs present in other RNA viral polymerases. The NS5B protein is fairly well conserved both intra-typically (˜95-98% amino acid (aa) identity across 1b isolates) and inter-typically (˜85% aa identity between genotype 1a and 1b isolates). The essentiality of the HCV NS5B RdRp activity for the generation of infectious progeny virions has been formally proven in chimpanzees (A. A. Kolykhalov et al. (2000) Journal of Virology, 74(4): 2046-2051). Thus, inhibition of NS5B RdRp activity (inhibition of RNA replication) is predicted to be useful to treat HCV infection.

Following the termination codon at the end of the long ORF, there is a 3′ NTR which roughly consists of three regions: an ˜40 base region which is poorly conserved among various genotypes, a variable length poly(U)/polypyrimidine tract, and a highly conserved 98 base element also called the “3′ X-tail” (Kolykhalov, A. et al. (1996) J. Virology 70:3363-3371; Tanaka, T. et al. (1995) Biochem Biophys. Res. Commun. 215744-749; Tanaka, T. et al. (1996) J. Virology 70:3307-3312; Yamada, N. et al. (1996) Virology 223:255-261). The 3′ NTR is predicted to form a stable secondary structure which is essential for HCV growth in chimps and is believed to function in the initiation and regulation of viral RNA replication.

Compounds useful for treating HCV-infected patients are desired which selectively inhibit HCV viral replication. In particular, compounds which are effective to inhibit the function of the NS5A protein are desired. The HCV NS5A protein is described, for example, in Tan, S.-L., Katzel, M. G. Virology 2001, 284, 1; and in Rice, C. M. Nature 2005, 435, 374.

Based on the foregoing, there exists a significant need to identify compounds with the ability to inhibit HCV.

SUMMARY OF THE INVENTION

The present invention relates to novel antiviral compounds represented herein below, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds. Compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents.

In its principal aspect, the present invention provides a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

Ring A and ring B are each independently optionally substituted phenyl or optionally substituted 6-membered heteroaryl containing one or more nitrogen atoms; preferably, ring A and ring B are each independently optionally substituted phenyl;

Ring G and ring W are each independently optionally substituted 5-membered heteroaryl containing one or more nitrogen atoms; preferably, ring G and ring W are each independently optionally substituted imidazolyl;

L¹ is selected from the group consisting of —C(O)—R¹, —C(O)—OR¹, —OC(O)—R¹, —C(O)—N(R¹)₂, —NR¹C(O)—OR¹, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, 3- to 7-membered heterocyclic and 5- to 7-membered heteroaryl, each optionally substituted; preferably, L¹ is optionally substituted C₃-C₇ cycloalkyl; in another embodiment, L¹ is optionally substituted 5- or 6-membered heteroaryl;

L² is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl) and amino optionally substituted with one or two C₁-C₄ alkyl; preferably, L² is hydrogen, halogen or hydroxy;

Alternatively L¹ and L² are taken together with the carbon atom to which they are attached to form a spiro 3- to 7-membered ring selected from the group consisting of optionally substituted 3- to 7-membered heterocyclic, optionally substituted C₃-C₇ cycloalkenyl, and substituted C₃-C₇ cycloalkyl, wherein said substituted C₃-C₇ cycloalkyl is substituted with at least one substituent other than C₁-C₆ alkyl; preferably, L¹ and L² are taken together with the carbon atom to which they are attached to form a spiro and optionally substituted 5-membered heterocyclic;

Y at each occurrence is independently C(O) or S(O)₂; preferably, Y is C(O);

R¹ at each occurrence is independently hydrogen or optionally substituted C₁-C₄ alkyl;

R³ and R⁴ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, and optionally substituted C₃-C₈ cycloalkyl; preferably, R³ and R⁴ are each independently hydrogen or optionally substituted C₁-C₄ alkyl; alternatively, R³ and R⁴ can be taken together with the carbon atom to which they are attached to form optionally substituted C₃-C₈ cycloalkyl or optionally substituted heterocyclic;

R⁵ is hydrogen, optionally substituted C₁-C₈ alkyl, or optionally substituted C₃-C₈ cycloalkyl; preferably, R⁵ is hydrogen or optionally substituted C₁-C₄ alkyl;

Alternatively R³, R⁴ and R⁵ are taken together with the carbon atom and nitrogen atom to which they are attached to form

U is absent or selected from O, S, S(O), SO₂, NC(O)—(C₁-C₄ alkyl), C(O), protected carbonyl, OCH₂, OCH₂CH₂, SCH₂, SCH₂CH₂, C(R⁷)₂, and C(R⁷)₂C(R⁷)₂;

R⁷ at each occurrence is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl), amino optionally substituted with one or two C₁-C₄ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₃-C₇ cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted C₁-C₄ alkyl; preferably, R⁷ is hydrogen, halogen, hydroxy, or optionally substituted C₃-C₇ cycloalkyl;

Alternatively two geminal R⁷ groups are taken together with the carbon atom to which they are attached to form a spiro, optionally substituted 3- to 7-membered ring selected from the group consisting of C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl and 3- to 7-membered heterocyclic, each optionally substituted; preferably, two geminal R⁷ groups are taken together with the carbon atom to which they are attached to form a spiro and optionally substituted cyclopropyl or 5-membered heterocyclic;

R^(7a) and R^(7b) at each occurrence are each independently selected from the group consisting of hydrogen, optionally substituted aryl, and optionally substituted C₁-C₄ alkyl; preferably, R^(7a) and R^(7b) at each occurrence are each independently hydrogen or methyl;

Alternatively, CHR^(7a)—U or CHR^(7b)—U are taken together to form a group selected from CH═CH, fused and optionally substituted C₃-C₈ cycloalkyl, fused and optionally substituted aryl, or fused and optionally substituted heterocyclic; preferably, CHR^(7a)—U or CHR^(7b)—U are taken together to form a fused and optionally substituted cyclopropyl;

Yet alternatively, U, R^(7a), and R^(7b) are taken together with the carbon atoms to which they are attached to form a bridged, optionally substituted 4- to 7-membered ring; in some embodiments, the optionally substituted 4- to 7-membered ring is selected from the group consisting of C₄-C₇ cycloalkyl, C₄-C₇ cycloalkenyl and 4- to 7-membered heterocyclic, each optionally substituted; preferably, U, R^(7a), and R^(7b) are taken together with the carbon atoms to which they are attached to form bridged cyclopentyl; and

R⁶ at each occurrence is independently selected from the group consisting of O(C₁-C₈ alkyl), amino, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, heterocyclic, aryl, and heteroaryl, each optionally substituted; preferably, R⁶ at each occurrence is independently optionally substituted C₁-C₈ alkyl; more preferably, R⁶ at each occurrence is independently C₁-C₈ alkyl optionally substituted with amino, cyano, halogen, hydroxy, protected amino, aryl, heteroaryl, or O(C₁-C₄ alkyl).

Each preferred group stated above can be taken in combination with one, any or all other preferred groups.

In another aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or combination of compounds of the present invention, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.

In yet another aspect, the present invention provides a method of inhibiting the replication of a RNA-containing virus comprising contacting said virus with a therapeutically effective amount of a compound or a combination of compounds of the present invention, or a pharmaceutically acceptable salt thereof. Particularly, this invention is directed to methods of inhibiting the replication of HCV.

In still another aspect, the present invention provides a method of treating or preventing infection caused by an RNA-containing virus comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or combination of compounds of the present invention, or a pharmaceutically acceptable salt thereof. Particularly, this invention is directed to methods of treating or preventing infection caused by HCV.

Yet another aspect of the present invention provides the use of a compound or combination of compounds of the present invention, or a therapeutically acceptable salt thereof, as defined hereinafter, in the preparation of a medicament for the treatment or prevention of infection caused by RNA-containing virus, specifically HCV.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds of Formula (I) as illustrated above, or a pharmaceutically acceptable salt thereof.

The compounds of the invention have utility in inhibiting the replication of RNA-containing virus, including, for example, HCV. Other compounds useful for inhibiting the replication of RNA-containing viruses and/or for the treatment or prophylaxis of HCV infection have been described in copending U.S. application Ser. No. 12/702,673 filed Feb. 9, 2010 entitled “Linked Dibenzimidazole Antivirals”; U.S. application Ser. No. 12/702,692 filed Feb. 9, 2010 entitled “Linked Dibenzimidazole Derivatives”; U.S. application Ser. No. 12/702,802 filed Feb. 9, 2010 entitled “Linked Dibenzimidazole Derivatives”; U.S. application Ser. No. 12/707,190 filed Feb. 17, 2010 entitled “Linked Diimidazole Antivirals”; U.S. application Ser. No. 12/707,200 filed Feb. 17, 2010 entitled “Linked Diimidazole Derivatives”; U.S. application Ser. No. 12/707,210 filed Feb. 17, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/714,583 filed Mar. 1, 2010 entitled “Novel Benzimidazole Derivatives”; U.S. application Ser. No. 12/714,576 filed Mar. 1, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/816,148 filed Jun. 15, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/816,171 filed Jun. 15, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/879,025 filed Sep. 10, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/879,026 filed Sep. 10, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/879,027 filed Sep. 10, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/879,028 filed Sep. 10, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/879,029 filed Sep. 10, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/879,031 filed Sep. 10, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. application Ser. No. 12/851,350 filed Aug. 5, 2010 entitled “Combination Pharmaceutical Agents As Inhibitors Of HCV Replication”; U.S. application Ser. No. 12/967,486 filed Dec. 14, 2010 entitled “Hepatitis C Virus Inhibitors”; U.S. Application Serial No. 13/013,212 filed Jan. 25, 2011 entitled “Hepatitis C Virus Inhibitors”; U.S. Application Serial No. 13/082,621 filed Apr. 8, 2011 entitled “Hepatitis C Virus Inhibitors” and U.S. Provisional Application Ser. No. 61/372,999 filed Aug. 12, 2010 entitled “Hepatitis C Virus Inhibitors;” and the contents of each of which are expressly incorporated by reference herein.

As discussed above, a general strategy for the development of antiviral agents is to inactivate virally encoded proteins, including NS5A, that are essential for the replication of the virus. The relevant patent disclosures describing the synthesis of HCV NS5A inhibitors are: US 2009/0202478; US 2009/0202483; US 2010/0233120; US 2010/0260708; WO 2004/014852; WO 2006/079833; WO 2006/133326; WO 2007/031791; WO 2007/070556; WO 2007/070600; WO 2007/082554; WO 2008/021927; WO 2008/021928; WO 2008/021936; WO 2008/048589; WO 2008/064218; WO 2008/070447; WO 2008/144380; WO 2008/154601; WO 2009/020825; WO 2009/020828; WO 2009/034390; WO 2009/102318; WO 2009/102325; WO 2009/102694; WO 2010/017401; WO 2010/039793; WO 2010/065668; WO 2010/065674; WO 2010/065681; WO 2010/091413; WO 2010/096777; WO 2010/096462; WO 2010/096302; WO2010/099527; WO 2010/111483; WO 2010/111534; WO 2010/117635; WO 2010/111673; WO 2010/117704; WO 2010/132538; WO 2010/132601; WO 2010/138488; WO 2010/138368; WO 2010/138790; WO 2010/138791; WO 2010/148006; US 2010/0215618; WO 2011/004276; WO 2011/009084; WO 2011/015657; WO 2011/015658; WO 2011/026920; WO 2011/028596; WO 2011/031904; WO 2011/031934; WO 2011/046811; WO 2011/050146 and WO 2011/054834, the contents of each of which are expressly incorporated by reference herein.

In one embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein both ring A and ring B are independently optionally substituted phenyl.

In another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein one of ring A and ring B is optionally substituted phenyl and the other one of ring A and ring B is optionally substituted 6-membered heteroaryl containing one or more nitrogen atoms. In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein one of ring A and ring B is optionally substituted phenyl and the other one of ring A and ring B is optionally substituted pyridyl, optionally substituted pyrazyl, optionally substituted pyrimidinyl or optionally substituted pyradizinyl.

In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein both ring A and ring B are independently optionally substituted 6-membered heteroaryl containing one or more nitrogen atoms. In another aspect, the present invention is directed to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein ring A and ring B are independently optionally substituted pyridyl, optionally substituted pyrazyl, optionally substituted pyrimidinyl or optionally substituted pyradizinyl.

In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ is —C(O)OCH₃; and L² is hydrogen.

In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ is selected from the group consisting of 5- to 7-membered heteroaryl, C₃-C₇ cycloalkyl and C₃-C₇ cycloalkenyl, and 3- to 7-membered heterocyclic, each optionally substituted; and L² is hydrogen. In an additional embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ is selected from the group consisting of 5- or 6-membered heteroaryl, C₃-C₇ cycloalkyl and C₃-C₇ cycloalkenyl, and 3- to 7-membered heterocyclic, each optionally substituted; and L² is hydrogen.

In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ is optionally substituted C₃-C₇ cycloalkyl; and L² is hydrogen. In a further embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ is a 5 to 7-membered heteroaryl or a 3- to 7-membered heterocyclic; and L² is hydrogen. In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ is a 5- or 6-membered heteroaryl or a 3- to 7-membered heterocyclic; and L² is hydrogen.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein ring A and ring B are each independently optionally substituted phenyl, L¹ is optionally substituted cyclopropyl; and L² is hydrogen. In certain additional embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein ring A and ring B are each independently optionally substituted phenyl, L¹ is a 5- to 7-membered heteroaryl or a 3- to 7-membered heterocyclic; and L² is hydrogen. In certain additional embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein ring A and ring B are each independently optionally substituted phenyl, L¹ is a 5 or 6-membered heteroaryl or a 3- to 7-membered heterocyclic; and L² is hydrogen.

In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ and L² are taken together with the carbon atom to which they are attached to form a spiro, optionally substituted 3- to 7-membered heterocyclic.

In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ and L² are taken together with the carbon atom to which they are attached to form a spiro, optionally substituted 3- to 7-membered cycloalkenyl.

In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein L¹ and L² are taken together with the carbon atom to which they are attached to form a spiro 3- to 7-membered substituted cycloalkyl, wherein said cycloalkyl is substituted with at least one substituent other than C₁-C₆ alkyl. In some aspects, the invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein L¹ and L² are taken together with the carbon atom to which they are attached to form a spiro, 3- to 7-membered cycloalkyl substituted with one or more halogen atoms.

In yet another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein each of ring G and ring W is C-attached at both points of attachment.

In still another embodiment, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof; wherein ring G and ring W are each independently illustrated by one of the following heteroaryl groups:

wherein each of the above shown heteroaryl groups is optionally substituted.

In yet another embodiment, the present invention relates to compounds of Formula (Ia) or (Ib), and pharmaceutically acceptable salts thereof;

wherein U, L¹, L², R¹, R³, R⁴, R⁵, R⁶, R^(7a) and R^(7b) are as previously defined.

In yet another embodiment, the present invention relates to compounds of Formula (Ia) or (Ib), and pharmaceutically acceptable salts thereof; wherein R¹ is hydrogen; R⁶ is optionally substituted C₁-C₈ alkyl; preferably, R₆ is C₁-C₈ alkyl optionally substituted with amino, cyano, halogen, hydroxy, protected amino, aryl, heteroaryl, or O(C₁-C₄ alkyl); and L¹ and L² are taken together with the carbon atom to which they are attached to form a spiro, 3- to 7-membered ring that is independently illustrated by one of the following groups:

wherein each of the above shown groups is optionally substituted and Rx is hydrogen or C₁-C₄ alkyl.

In still another embodiment, the present invention relates to compounds of Formula (Ib), and pharmaceutically acceptable salts thereof; wherein

is illustrated by one of the following groups:

wherein each of the above-shown groups are substituted with R¹, R^(7a) and R^(7b).

Representative compounds of the present invention are those selected from compounds I-288 and A1-A297 compiled in Tables 1-8 and Tables A1-A8:

TABLE 1 Compounds 1-219.

        Entry

 1

 2

 3

 4

 5

 6

 7

 8

 9

 10

 11

 12

 13

 14

 15

 16

 17

 18

 19

 20

 21

 22

 23

 24

 25

 26

 27

 28

 29

 30

 31

 32

 33

 34

 35

 36

 37

 38

 39

 40

 41

 42

 43

 44

 45

 46

 47

 48

 49

 50

 51

 52

 53

 54

 55

 56

 57

 58

 59

 60

 61

 62

 63

 64

 65

 66

 67

 68

 69

 70

 71

 72

 73

 74

 75

 76

 77

 78

 79

 80

 81

 82

 83

 84

 85

 86

 87

 88

 89

 90

 91

 92

 93

 94

 95

 96

 97

 98

 99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

TABLE 2 Compounds 220-229.

Entry R R′ R″ U Entry R R′ R″ U 220 Me H H CH₂ 221 H H H CF₂ 222 Me H H S 223 H H H

224 H Me H CH₂ 225 H H H

226 H Ph H CH₂ 227 H H H

228 H H Ph CH₂ 229 H H H

TABLE 3 Compounds 230-239.

Entry R R′ R″ Entry R R′ R″ 230 Me H H 231 H CO₂Me H 232 H CH₂OMe H 233 H H CO₂Me 234 H H CH₂OMe 235 H CH₂OH H 236 H Cl H 237 H H CH₂OH 238 H H Cl 239 Me CH₂OH H

TABLE 4 Compounds 240-249.

Entry R R′ R″ R′′′ Entry R R′ R″ R′′′ 240 F H H H 241 F F H H 242 Me H H H 243 Me Me H H 244 H H Me Me 245 H H Et Et 246 CF₃ H H H 247 CF₃ H CF₃ H 248 Cl H H H 249 Cl H Cl H

TABLE 5

Compounds 250-264. Entry R 250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

TABLE 6

Compounds 265-270. 265

266

267

268

269

270

TABLE 7

Compounds 271-276. Entry G^(g) 271

272

273

274

275

276

TABLE 8

Compounds 277-288. Entry

277

278

279

280

281

282

283

284

285

286

287

288

TABLE A1

Compounds Al -A219 . Entry

A1 

A2 

A3 

A4 

5A 

A6 

A7 

A8 

A9 

A10 

A11 

A12 

A13 

A14 

A15 

A16 

A17 

A18 

A19 

A20 

A21 

A22 

A23 

A24 

A25 

A26 

A27 

A28 

A29 

A30 

A31 

A32 

A33 

A34 

A35 

A36 

A37 

A38 

A39 

A40 

A41 

A42 

A43 

A44 

A45 

A46 

A47 

A48 

A49 

A50 

A51 

A52 

A53 

A54 

A55 

A56 

A57 

A58 

A59 

A60 

A61 

A62 

A63 

A64 

A65 

A66 

A67 

A68 

A69 

A70 

A71 

A72 

A73 

A74 

A75 

A76 

A77 

A78 

A79 

A80 

A81 

A82 

A83 

A84 

A85 

A86 

A87 

A88 

A89 

A90 

A91 

A92 

A93 

A94 

A95 

A96 

A97 

A98 

A99 

A100

A101

A102

A103

A104

A105

A106

A107

A108

A109

A110

A111

A112

A113

A114

A115

A116

A117

A118

A119

A120

A121

A122

A123

A124

A125

A126

A127

A128

A129

A130

A131

A132

A133

A134

A135

A136

A137

A138

A139

A140

A141

A142

A143

A144

A145

A146

A147

A148

A149

A150

A151

A152

A153

A154

A155

A156

A157

A158

A159

A160

A161

A162

A163

A164

A165

A166

A167

A168

A169

A170

A171

A172

A173

A174

A175

A176

A177

A178

A179

A180

A181

A182

A183

A184

A185

A186

A187

A188

A189

A190

A191

A192

A193

A194

A195

A196

A197

A198

A199

A200

A201

A202

A203

A204

A205

A206

A207

A208

A209

A210

A211

A212

A213

A214

A215

A216

A217

A218

A219

TABLE A2

Compounds A220-A229. Entry R R′ R″ U A220 Me H H CH₂ A221 H H H CF₂ A222 Me H H S A223 H H H

A224 H Me H CH₂ A225 H H H

A226 H Ph H CH₂ A227 H H H

A228 H H Ph CH₂ A229 H H H

TABLE A3

Compounds A230-A239. Entry R R′ R″ A230 Me H H A231 H CO₂Me H A232 H CH₂OMe H A233 H H CH₂Me A234 H H CH₂OMe A235 H CH₂OH H A236 H Cl H A237 H H CH₂OH A238 H H Cl A239 Me CH₂OH H

TABLE A4

Compounds A240-A249. Entry R R′ R″ R′′′ A240 F H H H A241 F F H H A242 Me H H H A243 Me Me H H A244 H H Me Me A245 H H Et Et A246 CF₃ H H H A247 CF₃ H CF₃ H A248 Cl H H H A249 Cl H Cl H

TABLE A5

Compounds A250-A276. Entry R A250

A251

A252

A253

A254

A255

A256

A257

A258

A259

A260

A261

A262

A263

A264

A265

A266

A267

A268

A269

A270

A271

A272

A273

A274

A275

A276

TABLE A6

Compounds A277-A282. Entry Aa A277

A278

A279

A280

A281

A282

TABLE A7

Compounds A283-A288. Entry Gg A283

A284

A285

A286

A287

A288

TABLE A8

Compounds A289-A297. Entry La Lb A289

H A290 H

A291 H CO₂Me A292

H A293 H

A294 CO₂Me H A295

H A296 H

A297

H

It will be appreciated that the description of the present invention herein should be construed in congruity with the laws and principals of chemical bonding. In some instances it may be necessary to remove a hydrogen atom in order to accommodate a substitutent at any given location.

It is intended that the definition of any substituent or variable (e.g., R¹, R⁶, U, Y, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule.

It will be yet appreciated that the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic, diastereoisomeric, and optically active forms. It will still be appreciated that certain compounds of the present invention may exist in different tautomeric forms. All tautomers are contemplated to be within the scope of the present invention.

It should be understood that the compounds encompassed by the present invention are those that are suitably stable for use as pharmaceutical agent.

It will be further appreciated that reference herein to therapy and/or treatment includes, but is not limited to, prevention, retardation, prophylaxis, therapy and/or cure of the disease. It will further be appreciated that references herein to treatment or prophylaxis of HCV infection includes treatment or prophylaxis of HCV-associated disease such as liver fibrosis, cirrhosis and hepatocellular carcinoma.

A further embodiment of the present invention includes pharmaceutical compositions comprising any single compound or a combination of two or more compounds delineated herein, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier or excipient.

Yet a further embodiment of the present invention is a pharmaceutical composition comprising any single compound or a combination of two or more compounds delineated herein, or a pharmaceutically acceptable salt thereof, in combination with one or more agents known in the art, with a pharmaceutically acceptable carrier or excipient.

It will be further appreciated that compounds of the present invention can be administered as the sole active pharmaceutical agent, or used in combination with one or more agents to treat or prevent hepatitis C infections or the symptoms associated with HCV infection. Other agents to be administered in combination with a compound or combination of compounds of the present invention include therapies for disease caused by HCV infection that suppresses HCV viral replication by direct or indirect mechanisms. These agents include, but are not limited to, host immune modulators (for example, interferon-alpha, pegylated interferon-alpha, consensus interferon, interferon-beta, interferon-gamma, CpG oligonucleotides and the like); antiviral compounds that inhibit host cellular functions such as inosine monophosphate dehydrogenase (for example, ribavirin and the like); cytokines that modulate immune function (for example, interleukin 2, interleukin 6, and interleukin 12); a compound that enhances the development of type 1 helper T cell response; interfering RNA; anti-sense RNA; vaccines comprising HCV antigens or antigen adjuvant combinations directed against HCV; agents that interact with host cellular components to block viral protein synthesis by inhibiting the internal ribosome entry site (IRES) initiated translation step of HCV viral replication or to block viral particle maturation and release with agents targeted toward the viroporin family of membrane proteins such as, for example, HCV P7 and the like; and any agent or combination of agents that inhibit the replication of HCV by targeting other proteins of the viral genome involved in the viral replication and/or interfere with the function of other viral targets, such as inhibitors of NS3/NS4A protease, NS3 helicase, NS5B polymerase, NS4A protein and NS5A protein.

According to yet another embodiment, the pharmaceutical compositions of the present invention may further comprise other inhibitor(s) of targets in the HCV life cycle, including, but not limited to, helicase, polymerase, metalloprotease, NS4A protein, NS5A protein, and internal ribosome entry site (IRES).

Accordingly, one embodiment of the present invention is directed to a method for treating or preventing an infection caused by an RNA-containing virus comprising co-administering to a patient in need of such treatment one or more agents selected from the group consisting of a host immune modulator and a second or more antiviral agents, or a combination thereof, with a therapeutically effective amount of a compound or combination of compounds of the present invention, or a pharmaceutically acceptable salt thereof. Examples of the host immune modulator include, but are not limited to, interferon-alpha, pegylated-interferon-alpha, interferon-beta, interferon-gamma, a cytokine, a vaccine, and a vaccine comprising an antigen and an adjuvant, and said second antiviral agent inhibits replication of HCV either by inhibiting host cellular functions associated with viral replication or by targeting proteins of the viral genome. A non-limiting example of the RNA-containing virus is Hepatitis C Virus (HCV).

A further embodiment of the present invention is directed to a method of treating or preventing infection caused by an RNA-containing virus comprising co-administering to a patient in need of such treatment an agent or combination of agents that treat or alleviate symptoms of HCV infection including cirrhosis and inflammation of the liver, with a therapeutically effective amount of a compound or combination of compounds of the present invention, or a pharmaceutically acceptable salt thereof. A non-limiting example of the RNA-containing virus is Hepatitis C Virus (HCV).

Yet another embodiment of the present invention provides a method of treating or preventing infection caused by an RNA-containing virus comprising co-administering to a patient in need of such treatment one or more agents that treat patients for disease caused by hepatitis B (HBV) infection, with a therapeutically effective amount of a compound or a combination of compounds of the present invention, or a pharmaceutically acceptable salt thereof. An agent that treats patients for disease caused by hepatitis B (HBV) infection may be for example, but not limited thereto, L-deoxythymidine, adefovir, lamivudine or tenfovir, or any combination thereof. A non-limiting example of the RNA-containing virus is Hepatitis C Virus (HCV).

A further embodiment of the present invention provides a method of treating or preventing infection caused by an RNA-containing virus comprising co-administering to a patient in need of such treatment one or more agents that treat patients for disease caused by human immunodeficiency virus (HIV) infection, with a therapeutically effective amount of a compound or a combination of compounds of the present invention, or a pharmaceutically acceptable salt thereof. The agent that treats patients for disease caused by human immunodeficiency virus (HIV) infection may include, but is not limited to, ritonavir, lopinavir, indinavir, nelfinavir, saquinavir, amprenavir, atazanavir, tipranavir, TMC-114, fosamprenavir, zidovudine, lamivudine, didanosine, stavudine, tenofovir, zalcitabine, abacavir, efavirenz, nevirapine, delavirdine, TMC-125, L-870812, S-1360, enfuvirtide (T-20) or T-1249, or any combination thereof. A non-limiting example of the RNA-containing virus is Hepatitis C Virus (HCV).

It can occur that a patient may be co-infected with Hepatitis C Virus and one or more other viruses, including but not limited to, human immunodeficiency virus (HIV), hepatitis A virus (HAV) and hepatitis B virus (HBV). Thus also contemplated herein is combination therapy to treat such co-infections by co-administering a compound according to the present invention with at least one of an HIV inhibitor, an HAV inhibitor and an HBV inhibitor.

In addition, the present invention provides the use of a compound or a combination of compounds of the invention, or a therapeutically acceptable salt thereof, and one or more agents selected from the group consisting of a host immune modulator and one or more additional antiviral agents, or a combination thereof, to prepare a medicament for the treatment of an infection caused by an RNA-containing virus in a patient, particularly Hepatitis C Virus. Examples of the host immune modulator include, but are not limited to, interferon-alpha, pegylated-interferon-alpha, interferon-beta, interferon-gamma, a cytokine, a vaccine, and a vaccine comprising an antigen and an adjuvant. Preferably, said additional antiviral agent inhibits replication of HCV either by inhibiting host cellular functions associated with viral replication or by targeting proteins of the viral genome.

When used in the above or other treatments, the combination of compound or compound of the present invention, together with one or more agents as defined herein above, can be employed in pure form or, where such forms exist, or as a pharmaceutically acceptable salt thereof. Alternatively, such combination of therapeutic agents can be administered as a pharmaceutical composition containing a therapeutically effective amount of the compound or combination of compounds of interest, or their pharmaceutically acceptable salt thereof, in combination with one or more agents as defined hereinabove, and a pharmaceutically acceptable carrier. Such pharmaceutical compositions can be used for inhibiting the replication of an RNA-containing virus, particularly Hepatitis C Virus (HCV), by contacting said virus with said pharmaceutical composition. In addition, such compositions are useful for the treatment or prevention of an infection caused by an RNA-containing virus, particularly Hepatitis C Virus (HCV).

Hence, a still further embodiment of the invention is directed to a method of treating or preventing infection caused by an RNA-containing virus, particularly a Hepatitis C Virus (HCV), comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a compound or combination of compounds of the invention or a pharmaceutically acceptable salt thereof, and one or more agents as defined herein above, with a pharmaceutically acceptable carrier.

When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or within a predetermined period of time, or the therapeutic agents can be given as a single unit dosage form.

Antiviral agents contemplated for use in such combination therapy include agents (compounds or biologicals) that are effective to inhibit the formation and/or replication of a virus in a mammal, including, but not limited to, agents that interfere with either host or viral mechanisms necessary for the formation and/or replication of a virus in a mammal. Such agents can be selected from another anti-HCV agent; an HIV inhibitor; an HAV inhibitor; and an HBV inhibitor.

Other agents that can be administered in combination with a compound of the present invention include a cytochrome P450 monooxygenase inhibitor (also referred to herein as a CYP inhibitor), which is expected to inhibit metabolism of the compounds of the invention. Therefore, the cytochrome P450 monooxygenase inhibitor would be in an amount effective to inhibit metabolism of the compounds of this invention. Accordingly, the CYP inhibitor is administered in an amount sufficient to improve one or more pharmacokinetic (PK) features including, but not limited to, plasma concentration, bioavailiablity, area under the plasma concentration time curve (AUC), elimination half-life, and systemic clearance, of a compound of the invention when one or more of its PK features of said compound is improved in comparison to that in the absence of the CYP inhibitor.

In one embodiment, the invention provides methods for improving the pharmacokinetics of compounds of the invention. The advantages of improving the pharmacokinetics of drugs are recognized in the art (see, for example, U.S. Patent Application Publication No's. US 2004/0152625 and US 2004/0091527). Accordingly, one embodiment of this invention provides a method comprising administering an inhibitor of CYP3A4 and a compound of the invention. Another embodiment of this invention provides a method comprising administering a compound of the invention and an inhibitor of isozyme 3A4 (“CYP3A4”), isozyme 2C19 (“CYP2C19”), isozyme 2D6 (“CYP2D6”), isozyme 1A2 (“CYP1A2”), isozyme 2C9 (“CYP2C9”), or isozyme 2E1 (“CYP2E1”). In a preferred embodiment, the CYP inhibitor preferably inhibits CYP3A4. Any CYP inhibitor that improves the pharmacokinetics of the relevant compound of the invention may be used in a method of this invention. These CYP inhibitors include, but are not limited to, ritonavir (see, for example, WO 94/14436), ketoconazole, troleandomycin, 4-methylpyrazole, cyclosporin, clomethiazole, cimetidine, itraconazole, fluconazole, miconazole, fluvoxamine, fluoxetine, nefazodone, sertraline, indinavir, nelfinavir, amprenavir, fosamprenavir, saquinavir, lopinavir, delavirdine, ditiazem, erythromycin, VX-944, and VX-497. Preferred CYP inhibitors include ritonavir, ketoconazole, troleandomycin, 4-methylpyrazole, cyclosporin, and clomethiazole.

It will be understood that the administration of the combination of the invention by means of a single patient pack, or patient packs of each formulation, containing within a package insert instructing the patient to the correct use of the invention is a desirable additional feature of this invention.

According to a further aspect of the invention is a pack comprising at least a compound of the invention and a CYP inhibitor and an information insert containing directions on the use of the combination of the invention. In an alternative embodiment of this invention, the pack further comprises one or more of additional agent as described herein. The additional agent or agents may be provided in the same pack or in separate packs.

Another aspect of this involves a packaged kit for a patient to use in the treatment of HCV infection or in the prevention of HCV infection, comprising: a single or a plurality of pharmaceutical formulation of each pharmaceutical component; a container housing the pharmaceutical formulation(s) during storage and prior to administration; and instructions for carrying out drug administration in a manner effective to treat or prevent HCV infection.

Accordingly, this invention provides kits for the simultaneous or sequential administration of a compound of the invention and a CYP inhibitor (and optionally an additional agent) or derivatives thereof are prepared in a conventional manner. Typically, such a kit will comprise, e.g., a composition of a compound of the invention and optionally the additional agent (s) in a pharmaceutically acceptable carrier (and in one or in a plurality of pharmaceutical formulations) and written instructions for the simultaneous or sequential administration.

In another embodiment, a packaged kit is provided that contains one or more dosage forms for self administration; a container means, preferably sealed, for housing the dosage forms during storage and prior to use; and instructions for a patient to carry out drug administration. The instructions will typically be written instructions on a package insert, a label, and/or on other components of the kit, and the dosage form or forms are as described herein. Each dosage form may be individually housed, as in a sheet of a metal foil-plastic laminate with each dosage form isolated from the others in individual cells or bubbles, or the dosage forms may be housed in a single container, as in a plastic bottle. The present kits will also typically include means for packaging the individual kit components, i.e., the dosage forms, the container means, and the written instructions for use. Such packaging means may take the form of a cardboard or paper box, a plastic or foil pouch, etc.

Definitions

Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.

The term “aryl,” as used herein, refers to a mono- or polycyclic carbocyclic ring system comprising at least one aromatic ring, including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, and idenyl. A polycyclic aryl is a polycyclic ring system that comprises at least one aromatic ring. Polycyclic aryls can comprise fused rings, covalently attached rings or a combination thereof.

The term “heteroaryl,” as used herein, refers to a mono- or polycyclic aromatic radical having one or more ring atom selected from S, O and N; and the remaining ring atoms are carbon, wherein any N or S contained within the ring may be optionally oxidized. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, and quinoxalinyl. A polycyclic heteroaryl can comprise fused rings, covalently attached rings or a combination thereof. In accordance with the invention, aromatic groups can be substituted or unsubstituted.

The term “bicyclic aryl” or “bicyclic heteroaryl” refers to a ring system consisting of two rings wherein at least one ring is aromatic; and the two rings can be fused or covalently attached.

The terms “C₁-C₄ alkyl,” “C₁-C₆ alkyl,” “C₁-C₈ alkyl,” “C₂-C₄ alkyl,” or “C₃-C₆ alkyl,” as used herein, refer to saturated, straight- or branched-chain hydrocarbon radicals containing between one and four, one and six, one and eight carbon atoms, or the like, respectively. Examples of C₁-C₈ alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl, heptyl and octyl radicals.

The terms “C₂-C₈ alkenyl,” “C₂-C₄ alkenyl,” “C₃-C₄ alkenyl,” or “C₃-C₆ alkenyl,” as used herein, refer to straight- or branched-chain hydrocarbon radicals containing from two to eight, or two to four carbon atoms, or the like, having at least one carbon-carbon double bond by the removal of a single hydrogen atom. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl, and the like.

The terms “C₂-C₈ alkynyl,” “C₂-C₄ alkynyl,” “C₃-C₄ alkynyl,” or “C₃-C₆ alkynyl,” as used herein, refer to straight- or branched-chain hydrocarbon radicals containing from two to eight, or two to four carbon atoms, or the like, having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and the like.

The term “C₃-C₈-cycloalkyl”, “C₅-C₇-cycloalkyl,” “C₃-C₇-cycloalkyl,” or “C₄-C₇ cycloalkyl” as used herein, refers to a monocyclic or polycyclic saturated carbocyclic ring compound, and the carbon atoms may be optionally oxo-substituted. Examples of C₃-C₈-cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl and cyclooctyl; and examples of C₅-C₇-cycloalkyl include, but not limited to, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, and the like.

The term “C₃-C₈ cycloalkenyl”, “C₅-C₇ cycloalkenyl,” “C₃-C₇-cycloalkenyl,” or “C₄-C₇ cycloalkenyl” as used herein, refers to monocyclic or polycyclic carbocyclic ring compound having at least one carbon-carbon double bond, and the carbon atoms may be optionally oxo-substituted. Examples of C₃-C₈ cycloalkenyl include, but not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like; and examples of C₅-C₇ cycloalkenyl include, but not limited to, cyclopentenyl, cyclohexenyl, cycloheptenyl, and the like.

The term “arylalkyl”, as used herein, refers to an aryl-substituted alkyl group. More preferred arylalkyl groups are aryl-C₁-C₆-alkyl groups.

The term “heteroarylalkyl”, as used herein, refers to a heteroaryl-substituted alkyl group. More preferred heteroarylalkyl groups are heteroaryl-C₁-C₆-alkyl groups.

It is understood that any alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic and cycloalkenyl moiety described herein can also be an aliphatic group or an alicyclic group.

An “aliphatic” group is a non-aromatic moiety comprised of any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally contains one or more units of unsaturation, e.g., double and/or triple bonds.

The term “alicyclic,” as used herein, denotes a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom, and the carbon atoms may be optionally oxo-substituted. Examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, and bicyclo[2.2.2]octyl. Such alicyclic groups may be further substituted.

The terms “heterocyclic” or “heterocycloalkyl” can be used interchangeably and referred to a non-aromatic ring or a bi- or tri-cyclic group fused system, where (i) each ring system contains at least one heteroatom independently selected from oxygen, sulfur and nitrogen, (ii) each ring system can be saturated or unsaturated (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, (v) any of the above rings may be fused to an aromatic ring, and (vi) the remaining ring atoms are carbon atoms which may be optionally oxo-substituted. Representative heterocycloalkyl groups include, but are not limited to, 1,3-dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, and tetrahydrofuryl. Such heterocyclic groups may be further substituted. Heteroaryl or heterocyclic groups can be C-attached or N-attached (where possible).

It is understood that any alkyl, alkenyl, alkynyl, alicyclic, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclic, aliphatic moiety or the like, described herein can also be a divalent or multivalent group when used as a linkage to connect two or more groups or substituents, which can be at the same or different atom(s).

The term “substituted” refers to substitution by independent replacement of one, two, or three or more of the hydrogen atoms with substituents including, but not limited to, —F, —Cl, —Br, —I, —OH, protected hydroxy, —NO₂, —N₃, —CN, —NH₂, protected amino, oxo, thioxo, —NH—C₁-C₁₂-alkyl, —NH—C₂-C₈-alkenyl, —NH—C₂-C₈-alkynyl, —NH—C₃-C₁₂-cycloalkyl, —NH-aryl, —NH-heteroaryl, —NH-heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, —O—C₁-C₁₂-alkyl, —O—C₂-C₈-alkenyl, —O—C₂-C₈-alkynyl, —O—C₃-C₁₂-cycloalkyl, —O-aryl, —O-heteroaryl, —O-heterocycloalkyl, —C(O)—C₁-C₁₂-alkyl, —C(O)—C₂-C₈-alkenyl, —C(O)—C₂-C₈-alkynyl, —C(O)—C₃-C₁₂-cycloalkyl, —C(O)-aryl, —C(O)-heteroaryl, —C(O)-heterocycloalkyl, —CONH₂, —CONH—C₁-C₁₂-alkyl, —CONH—C₂-C₈-alkenyl, —CONH—C₂-C₈-alkynyl, —CONH—C₃-C₁₂-cycloalkyl, —CONH-aryl, —CONH-heteroaryl, —CONH-heterocycloalkyl, —OCO₂—C₁-C₁₂-alkyl, —OCO₂—C₂-C₈-alkenyl, —OCO₂—C₂-C₈-alkynyl, —OCO₂—C₃-C₁₂-cycloalkyl, —OCO₂-aryl, —OCO₂-heteroaryl, —OCO₂-heterocycloalkyl, —CO₂—C₁-C₁₂ alkyl, —CO₂—C₂-C₈ alkenyl, —CO₂—C₂-C₈ alkynyl, CO₂—C₃-C₁₂-cycloalkyl, —CO₂— aryl, CO₂-heteroaryl, CO₂-heterocycloalkyl, —OCONH₂, —OCONH—C₁-C₁₂-alkyl, —OCONH—C₂-C₈-alkenyl, —OCONH—C₂-C₈-alkynyl, —OCONH—C₃-C₁₂-cycloalkyl, —OCONH-aryl, —OCONH-heteroaryl, —OCONH— heterocycloalkyl, —NHC(O)H, —NHC(O)—C₁-C₁₂-alkyl, —NHC(O)—C₂-C₈-alkenyl, —NHC(O)—C₂-C₈-alkynyl, —NHC(O)—C₃-C₁₂-cycloalkyl, —NHC(O)-aryl, —NHC(O)-heteroaryl, —NHC(O)-heterocycloalkyl, —NHCO₂—C₁-C₁₂-alkyl, —NHCO₂—C₂-C₈-alkenyl, —NHCO₂—C₂-C₈-alkynyl, —NHCO₂—C₃-C₁₂-cycloalkyl, —NHCO₂-aryl, —NHCO₂-heteroaryl, —NHCO₂— heterocycloalkyl, —NHC(O)NH₂, —NHC(O)NH—C₁-C₁₂-alkyl, —NHC(O)NH—C₂-C₈-alkenyl, —NHC(O)NH—C₂-C₈-alkynyl, —NHC(O)NH—C₃-C₁₂-cycloalkyl, —NHC(O)NH-aryl, —NHC(O)NH-heteroaryl, —NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, —NHC(S)NH—C₁-C₁₂-alkyl, —NHC(S)NH—C₂-C₈-alkenyl, —NHC(S)NH—C₂-C₈-alkynyl, —NHC(S)NH—C₃-C₁₂-cycloalkyl, —NHC(S)NH-aryl, —NHC(S)NH-heteroaryl, —NHC(S)NH-heterocycloalkyl, —NHC(NH)NH₂, —NHC(NH)NH—C₁-C₁₂-alkyl, —NHC(NH)NH—C₂-C₈-alkenyl, —NHC(NH)NH—C₂-C₈-alkynyl, —NHC(NH)NH—C₃-C₁₂-cycloalkyl, —NHC(NH)NH-aryl, —NHC(NH)NH-heteroaryl, —NHC(NH)NH-heterocycloalkyl, —NHC(NH)—C₁-C₁₂-alkyl, —NHC(NH)—C₂-C₈-alkenyl, —NHC(NH)—C₂-C₈-alkynyl, —NHC(NH)—C₃-C₁₂-cycloalkyl, —NHC(NH)-aryl, —NHC(NH)-heteroaryl, —NHC(NH)-heterocycloalkyl, —C(NH)NH—C₁-C₁₂-alkyl, —C(NH)NH—C₂-C₈-alkenyl, —C(NH)NH—C₂-C₈-alkynyl, —C(NH)NH—C₃-C₁₂-cycloalkyl, —C(NH)NH-aryl, —C(NH)NH-heteroaryl, —C(NH)NH-heterocycloalkyl, —S(O)—C₁-C₁₂-alkyl, —S(O)—C₂-C₈-alkenyl, —S(O)—C₂-C₈-alkynyl, —S(O)—C₃-C₁₂-cycloalkyl, —S(O)-aryl, —S(O)-heteroaryl, —S(O)-heterocycloalkyl, —SO₂NH₂, —SO₂NH—C₁-C₁₂-alkyl, —SO₂NH—C₂-C₈-alkenyl, —SO₂NH—C₂-C₈-alkynyl, —SO₂NH—C₃-C₁₂-cycloalkyl, —SO₂NH-aryl, —SO₂NH-heteroaryl, —SO₂NH— heterocycloalkyl, —NHSO₂—C₁-C₁₂-alkyl, —NHSO₂—C₂-C₈-alkenyl, —NHSO₂—C₂-C₈-alkynyl, —NHSO₂—C₃-C₁₂-cycloalkyl, —NHSO₂-aryl, —NHSO₂-heteroaryl, —NHSO₂-heterocycloalkyl, —CH₂NH₂, —CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, —C₃-C₁₂-cycloalkyl, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy, -methoxyethoxy, —SH, —S—C₁-C₁₂-alkyl, —S—C₂-C₈-alkenyl, —S—C₂-C₈-alkynyl, —S—C₃-C₁₂-cycloalkyl, —S-aryl, —S-heteroaryl, —S-heterocycloalkyl, or methylthiomethyl. It is understood that the aryls, heteroaryls, alkyls, and the like can be further substituted.

The term “halogen,” as used herein, refers to an atom selected from fluorine, chlorine, bromine and iodine.

The term “hydrogen” includes hydrogen and deuterium. In addition, the recitation of an atom includes other isotopes of that atom so long as the resulting compound is pharmaceutically acceptable.

The term “hydroxy activating group”, as used herein, refers to a labile chemical moiety which is known in the art to activate a hydroxyl group so that it will depart during synthetic procedures such as in a substitution or an elimination reaction. Examples of hydroxyl activating group include, but not limited to, mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate and the like.

The term “activated hydroxy”, as used herein, refers to a hydroxy group activated with a hydroxyl activating group, as defined above, including mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate groups, for example.

The term “hydroxy protecting group,” as used herein, refers to a labile chemical moiety which is known in the art to protect a hydroxyl group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed. Hydroxy protecting groups as known in the art are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxyl protecting groups include benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, tert-butoxycarbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, t-butyl, 2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, allyl, benzyl, triphenyl-methyl (trityl), methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-(trimethylsilyl)-ethoxymethyl, methanesulfonyl, trimethylsilyl, triisopropylsilyl, and the like.

The term “protected hydroxy,” as used herein, refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.

The term “hydroxy prodrug group”, as used herein, refers to a promoiety group which is known in the art to change the physicochemical, and hence the biological properties of a parent drug in a transient manner by covering or masking the hydroxy group. After said synthetic procedure(s), the hydroxy prodrug group as described herein must be capable of reverting back to hydroxy group in vivo. Hydroxy prodrug groups as known in the art are described generally in Kenneth B. Sloan, Prodrugs, Topical and Ocular Drug Delivery, (Drugs and the Pharmaceutical Sciences; Volume 53), Marcel Dekker, Inc., New York (1992).

The term “amino protecting group,” as used herein, refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed. Amino protecting groups as known in the art are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, methoxycarbonyl, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.

The term “protected amino,” as used herein, refers to an amino group protected with an amino protecting group as defined above.

The term “leaving group” means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction. By way of example, representative leaving groups include chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.

The term “aprotic solvent,” as used herein, refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor. Examples include, but are not limited to, hydrocarbons, such as hexane and toluene, for example, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran and N-methylpyrrolidinone, and ethers such as diethyl ether, bis-methoxymethyl ether. Such compounds are well known to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, NY, 1986.

The term “protic solvent” as used herein, refers to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, and the like. Such solvents are well known to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of protogenic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, NY, 1986.

Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term “stable”, as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).

The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the Formula herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, 2^(nd) Ed. Wiley-VCH (1999); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

The term “subject” as used herein refers to an animal. Preferably, the animal is a mammal. More preferably, the mammal is a human. A subject also refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, fish, birds and the like.

The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and may include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, et al., Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). When the compounds described herein contain olefinic double bonds, other unsaturation, or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers or cis- and trans-isomers. Likewise, all tautomeric forms are also intended to be included. Tautomers may be in cyclic or acyclic. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond or carbon-heteroatom double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.

Certain compounds of the present invention may also exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The present invention includes each conformational isomer of these compounds and mixtures thereof.

As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.

As used herein, the term “pharmaceutically acceptable ester” refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

The term “pharmaceutically acceptable prodrugs” as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. “Prodrug”, as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of the invention. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). “Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38 (1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq. (1988); Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975); and Bernard Testa & Joachim Mayer, “Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology,” John Wiley and Sons, Ltd. (2002).

The present invention also relates to solvates of the compounds of Formula (I), for example hydrates.

This invention also encompasses pharmaceutical compositions containing, and methods of treating viral infections through administering, pharmaceutically acceptable prodrugs of compounds of the invention. For example, compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.

Pharmaceutical Compositions

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.

As used herein, the term “pharmaceutically acceptable carrier or excipient” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

For pulmonary delivery, a therapeutic composition of the invention is formulated and administered to the patient in solid or liquid particulate form by direct administration e.g., inhalation into the respiratory system. Solid or liquid particulate forms of the active compound prepared for practicing the present invention include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. Delivery of aerosolized therapeutics, particularly aerosolized antibiotics, is known in the art (see, for example U.S. Pat. No. 5,767,068 to VanDevanter et al., U.S. Pat. No. 5,508,269 to Smith et al., and WO 98/43650 by Montgomery, all of which are incorporated herein by reference). A discussion of pulmonary delivery of antibiotics is also found in U.S. Pat. No. 6,014,969, incorporated herein by reference.

Antiviral Activity

An inhibitory amount or dose of the compounds of the present invention may range from about 0.01 mg/Kg to about 500 mg/Kg, alternatively from about 1 to about 50 mg/Kg. Inhibitory amounts or doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.

According to the methods of treatment of the present invention, viral infections, conditions are treated or prevented in a patient such as a human or another animal by administering to the patient a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to achieve the desired result.

By a “therapeutically effective amount” of a compound of the invention is meant an amount of the compound which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). An effective amount of the compound described above may range from about 0.1 mg/Kg to about 500 mg/Kg, preferably from about 1 to about 50 mg/Kg. Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or contemporaneously with the specific compound employed; and like factors well known in the medical arts.

The total daily dose of the compounds of this invention administered to a human or other animal in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses.

The compounds of the present invention described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.1 to about 500 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with pharmaceutically excipients or carriers to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations may contain from about 20% to about 80% active compound.

Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.

Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

When the compositions of this invention comprise a combination of a compound of the Formula described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

The said “additional therapeutic or prophylactic agents” includes but not limited to, immune therapies (e.g. interferon), therapeutic vaccines, antifibrotic agents, anti-inflammatory agents such as corticosteroids or NSAIDs, bronchodilators such as beta-2 adrenergic agonists and xanthines (e.g. theophylline), mucolytic agents, anti-muscarinics, anti-leukotrienes, inhibitors of cell adhesion (e.g. ICAM antagonists), anti-oxidants (e.g. N-acetylcysteine), cytokine agonists, cytokine antagonists, lung surfactants and/or antimicrobial and anti-viral agents (e.g. ribavirin and amantidine). The compositions according to the invention may also be used in combination with gene replacement therapy.

Combination and Alternation Therapy for HCV

It has been recognized that drug-resistant variants of HCV can emerge after prolonged treatment with an antiviral agent. Drug resistance most typically occurs by mutation of a gene that encodes for a protein such as an enzyme used in viral replication, and most typically in the case of HCV, RNA polymerase, protease, or helicase.

Recently, it has been demonstrated that the efficacy of a drug against a viral infection, such as HIV, can be prolonged, augmented, or restored by administering the drug in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation from that caused by the principal drug. Alternatively, the pharmacokinetics, biodistribution, or other parameter of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.

A compound of the present invention can also be administered in combination or alternation with antiviral agent. Exemplary antiviral agents include ribavarin, interferon, interleukin or a stabilized prodrug of any of them. More broadly described, the compound can be administered in combination or alternation with any of the anti-HCV drugs listed in Table 9 below.

TABLE 9 Table of anti-Hepatitis C Compounds in Current Clinical Development Drug name Drug category Pharmaceutical Company PEGASYS Long acting interferon Roche pegylated interferon alfa-2a INFERGEN Long acting interferon InterMune interferon alfacon-1 OMNIFERON Long acting interferon Viragen natural interferon ALBUFERON Long acting interferon Human Genome Sciences REBIF interferon beta-la Interferon Ares-Serono Omega Interferon Interferon BioMedicine Oral Interferon alpha Oral Interferon Amarillo Biosciences Interferon gamma-lb Anti-fibrotic InterMune IP-501 Anti-fibrotic InterMune Merimebodib VX-497 IMPDH inhibitor Vertex (inosine monophosphate dehydrogenase) AMANTADINE (Symmetrel) Broad Antiviral Agent Endo Labs Solvay IDN-6556 Apotosis regulation Idun Pharma. XTL-002 Monclonal Antibody XTL HCV/MF59 Vaccine Chiron CIVACIR Polyclonal Antibody NABI Innogenetics Therapeutic vaccine VIRAMIDINE Nucleoside Analogue ICN ZADAXIN (thymosin alfa-1) Immunomodulator Sci Clone CEPLENE (histamine) Immunomodulator Maxim VX 950/LY 570310 Protease inhibitor Vertex/Eli Lilly ISIS 14803 Antisense Isis Pharmaceutical/Elan IDN-6556 Caspase inhibitor Idun Pharmaceuticals JTK 003 Polymerase Inhibitor AKROS Pharma Tarvacin Anti-Phospholipid Therapy Peregrine HCV-796 Polymerase Inhibitor ViroPharma/Wyeth CH-6 Protease inhibitor Schering ANA971 Isatoribine ANADYS ANA245 Isatoribine ANADYS CPG 10101 (Actilon) Immunomodulator Coley Rituximab (Rituxam) Anti-CD2O Genetech/IDEC Monoclonal Antibody NM283 (Valopicitabine) Polymerase Inhibitor Idenix Pharmaceuticals HepX ™-C Monoclonal Antibody XTL IC41 Therapeutic Vaccine Intercell Medusa Interferon Longer acting interferon Flamel Technology E-1 Therapeutic Vaccine Innogenetics Multiferon Long Acting Interferon Viragen BILN 2061 Protease inhibitor Boehringer-Ingelheim TMC435350 Protease inhibitor Tibotec/Medivir Telaprevir (VX-950) Protease inhibitor Vertex Boceprevir (SCH 503034) Protease inhibitor Schering-Plough ACH-1625 Protease inhibitor Achillion ABT-450 Protease inhibitor Abbott/Enanta BI-201335 Protease inhibitor Boehringer-Ingelheim PHX-1766 Protease inhibitor Phenomix VX-500 Protease inhibitor Vertex MK-7009 protease inhibitor Merck R7227 (ITMN-191) protease inhibitor InterMune Narlaprevir (SCH 900518) Protease inhibitor Schering/Merck Alinia (nitazoxanide) To be determined Romark ABT-072 Polymerase Inhibitor Abbott ABT-333 Polymerase Inhibitor Abbott Filibuvir (PF-00868554) Polymerase Inhibitor Pfizer VCH-916 Polymerase Inhibitor Vertex R7128 (PSI6130) Polymerase Inhibitor Roche/Pharmasset IDX184 Polymerase Inhibitor Idenix INX-189 Polymerase Inhibitor Inhibitex PSI-7977 Polymerase Inhibitor Pharmasset PSI-938 Polymerase Inhibitor Pharmasset R1626 Polymerase inhibitor Roche MK-3281 Polymerase inhibitor Merck PSI-7851 Polymerase inhibitor Pharmasset ANA598 Polymerase inhibitor Anadys Pharmaceuticals BI-207127 Polymerase inhibitor Boehringer-Ingelheim GS-9190 Polymerase inhibitor Gilead VCH-759 Polymerase Inhibitor Vertex Clemizole NS4B inhibitor Eiger Biopharmaceuticals A-832 NS5A inhibitor ArrowTherapeutics BMS-790052 NS5A inhibitor Bristol-Myers-Squibb BMS-824393 NS5A inhibitor Bristol-Myers-Squibb GS-5885 NS5A inhibitor Gilead ITX5061 Entry inhibitor iTherx GS-9450 Caspase inhibitor Gilead ANA773 TLR agonist Anadys CYT107 immunomodulator Cytheris SPC3649 (LNA-antimiR ™-122) microRNA Santaris Pharma Debio 025 Cyclophilin inhibitor Debiopharm SCY-635 Cyclophilin inhibitor Scynexis

Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one of ordinary skill in the art. All publications, patents, published patent applications, and other references mentioned herein are hereby incorporated by reference in their entirety.

Abbreviations

Abbreviations which may be used in the descriptions of the scheme and the examples that follow are: Ac for acetyl; AcOH for acetic acid; AIBN for azobisisobutyronitrile; BINAP for 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl; Boc₂O for di-tert-butyl-dicarbonate; Boc for t-butoxycarbonyl; Bpoc for 1-methyl-1-(4-biphenylyl)ethyl carbonyl; BtOH for 1-hydroxybenzotriazole; Bz for benzoyl; Bn for benzyl; BocNHOH for tert-butyl N-hydroxycarbamate; t-BuOK for potassium tert-butoxide; Bu₃SnH for tributyltin hydride; BOP for (benzotriazol-1-yloxy)tris(dimethylamino)phos-phonium Hexafluorophosphate; Brine for sodium chloride solution in water; Cbz for carbobenzyloxy; CDI for carbonyldiimidazole; CH₂Cl₂ for dichloromethane; CH₃ for methyl; CH₃CN for acetonitrile; Cs₂CO₃ for cesium carbonate; CuCl for copper (I) chloride; CuI for copper (I) iodide; dba for dibenzylidene acetone; dppb for diphenylphosphino butane; DBU for 1,8-diazabicyclo[5.4.0]undec-7-ene; DCC for N,N′-dicyclohexylcarbodiimide; DEAD for diethylazodicarboxylate; DIAD for diisopropyl azodicarboxylate; DIBAL-H for diisobutylaluminium hydride; DIPEA or (i-Pr)₂EtN for N,N-diisopropylethyl amine; Dess-Martin periodinane for 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one; DMAP for 4-dimethylaminopyridine; DME for 1,2-dimethoxy-ethane; DMF for N,N-dimethylformamide; DMSO for dimethyl sulfoxide; DMT for di(p-methoxyphenyl)phenylmethyl or dimethoxytrityl; DPPA for diphenylphosphoryl azide; EDC for N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide; EDC HCl for N-(3-dimethylamino-propyl)-N′-ethylcarbodiimide hydrochloride; EtOAc for ethyl acetate; EtOH for ethanol; Et₂O for diethyl ether; Fmoc for 9-fluorenylmethoxycarbonyl; Grubbs-1 catalyst for benzylidene-bis(tricyclohexylphosphine)dichlororuthenium; HATU for O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; HCl for hydrogen chloride; HOBT for 1-hydroxybenzotriazole; K₂CO₃ for potassium carbonate; n-BuLi for n-butyl lithium; i-BuLi for i-butyl lithium; t-BuLi for t-butyl lithium; PhLi for phenyl lithium; LDA for lithium diisopropylamide; LiTMP for lithium 2,2,6,6-tetramethylpiperidinate; MeOH for methanol; Mg for magnesium; MOM for methoxymethyl; Ms for mesyl or —SO₂—CH₃; Ms₂O for methanesulfonic anhydride or mesyl-anhydride; NaBH₄ for sodium borohydride; NaBH₃CN for sodium cyanoborohydride; NaN(TMS)₂ for sodium bis(trimethylsilyl)amide; NaCl for sodium chloride; NaH for sodium hydride; NaHCO₃ for sodium bicarbonate or sodium hydrogen carbonate; Na₂CO₃ sodium carbonate; NaOH for sodium hydroxide; Na₂SO₄ for sodium sulfate; NaHSO₃ for sodium bisulfite or sodium hydrogen sulfite; Na₂S₂O₃ for sodium thiosulfate; NH₂NH₂ for hydrazine; NH₄HCO₃ for ammonium bicarbonate; NH₄Cl for ammonium chloride; NMMO for N-methylmorpholine N-oxide; NaIO₄ for sodium periodate; Ni for nickel; OH for hydroxyl; OsO₄ for osmium tetroxide; Pd for palladium; Ph for phenyl; PMB for p-methoxybenzyl; POPd for dihydrogen dichlorobis(di-tert-butylphosphinito-KP)palladate(II); Pd₂(dba)₃ for tris(dibenzylidene-acetone) dipalladium (0); Pd(PPh₃)₄ for tetrakis(triphenylphosphine)palladium (0); PdCl₂(dppf) for dichloro[1,1′-bis(diphenyl-phosphino)ferrocene]palladium (II) dichloromethane adduct; PdCl₂(PPh₃)₂ for trans-dichlorobis(triphenyl-phosphine)palladium (II); Pt for platinum; Rh for rhodium; rt for romm temperature; Ru for ruthenium; SEM for (trimethylsilyl)ethoxymethyl; TBAF for tetrabutylammonium fluoride; TBS for tert-butyl dimethylsilyl; TEA or Et₃N for triethylamine; Teoc for 2-trimethylsilyl-ethoxy-carbonyl; TFA for trifluoroacetic acid; THF for tetrahydrofuran; TMEDA for N,N,N′,N′-tetramethylethylenediamine; TPP or PPh₃ for triphenyl-phosphine; Troc for 2,2,2-trichloroethyl carbonyl; Ts for tosyl or —SO₂—C₆H₄—CH₃; Ts₂O for tolylsulfonic anhydride or tosyl-anhydride; TsOH for p-tolylsulfonic acid; TMS for trimethylsilyl; TMSCl for trimethylsilyl chloride; or TMS₃SiH for tris(trimethylsilyl)silane.

Synthetic Methods

The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes that illustrate the methods by which the compounds of the invention may be prepared. Starting materials can be obtained from commercial sources or prepared by well-established literature methods known to those of ordinary skill in the art. It will be readily apparent to one of ordinary skill in the art that the compounds described above can be synthesized by substitution of the appropriate reactants and agents in the syntheses shown below. It will also be readily apparent to one skilled in the art that the selective protection and deprotection steps, as well as the order of the steps themselves, can be carried out in varying order, depending on the nature of the variables to successfully complete the syntheses below. The variables are as defined above unless otherwise noted below.

The compounds of the present invention may be prepared via several different synthetic routes from a variety of 5-membered ring heteroaryl and related intermediates. An exemplary method is shown in Schemes 1 to 6. A retro-synthesis of those title compounds include direct formation of a suitable 5-membered ring heteroaryl, followed by attachment of a suitable capping group (such as —C(O)R⁶), plus some functional group manipulations in between and/or after. Various 5-membered ring heteroaryl intermediates are known to those skilled in the art, for example see the encyclopedic volumes edited by A. R. Katrizky, et al, “Comprehensive Heterocyclic Chemistry” 1984; “Comprehensive Heterocyclic Chemistry II” 1996; “Comprehensive Heterocyclic Chemistry III” 2008.

A typical synthesis of imidazole and related intermediates are illustrated in Scheme 1. Bromo-imidazole 1-2 can be synthesized by condensation of an amino acid-derived aldehyde 1-1.1 and glyoxal in the presence of methanolic ammonia; followed by bromination of the imidazole ring under the conditions which are known to those skilled in the art. The mono-bromination of the imidazole ring may be realized either in one pot by NBS, bromine, 2,4,4,6-tetrabromo-2,5-cyclohexadienone, or the like; or in two steps: 1) dibromide formation in the presence of excess bromination reagent such as NBS, bromine, 2,4,4,6-tetrabromo-2,5-cyclohexadienone, or the like, optionally with heat; and 2) reduction of the dibromide to monobromide in the presence of a reducing reagent such as NaHSO₃, Na₂S₂O₃, Na₂SO₃, or the like. Bromide 1-2 then may be served as a common intermediate further elaborable to many other imidazole derivatives. For example, bromide 1-2 may be converted to key intermediate 1-4 by selectively reacting with metallic reagent 1-2.1 under the Suzuki or Stille conditions. Alternatively, intermediate 1-4 may be prepared by treating bromide 1-2 with dimetallic agent 1-2.2 to afford organometallic 1-5, followed by coupling with bromoiodoaryl or bromoiodoheteroaryl compound 1-5.1, both may be under the previously described Suzuki or Stille reaction conditions. The bromide 1-4 may be further converted to organometallic 1-7 with dimetallic agent 1-4.1 using the conditions described above for the preparation of intermediate 1-5.

Yet alternatively, aryl or heteroaryl bromide 1-4 may also be derived from bromoketone 1-9, which can be prepared from the corresponding ketone 1-8 in the presence of a bromination reagent such as NBS, bromine, or the like, optionally in the presence of an acid and/or with heating. Bromoketone 1-9 may be either converted to the corresponding amine 1-11 through azide substitution followed by reduction, or coupled with protected amino acid Q¹-CO₂H 1-1.2 in the presence of a base such as Et₃N or DIPEA to afford keto-ester 1-10. Similarly, amine 1-11 may be converted to the corresponding keto-amide 1-12 via condensation with appropriate amino acid under standard amide formation conditions. Both 1-10 and 1-12 may be transformed to key intermediate 1-4 via heating with NH₄OAc under thermal or microwave conditions.

It should be noted that optionally the NH group of all the imidazopyridine related intermediates listed above may be protected with an amino protecting group, such as SEM (i.e. SEM-Cl, NaH), Boc, Cbz, Teoc, Troc, or the like.

Alternatively, some of the substituted imidazole intermediates may be synthesized from ketone 2-1 (Scheme 2) through nitrosation (sodium nitrite, HCl) to ketooxime 2-2, which may be cyclized with aldehyde 1-1.1 to 1-hydroxyimidazole 2-3 in the presence of ammonia or ammonium hydroxide. Reduction of 2-3 with a suitable reducing reagent such as triethyl phosphite may lead to the requisite imidazole 2-4.

The starting materials illustrated in Scheme 1 and 2, such as the protected amino acid 1-1.2 and the aldehyde 1-1.1 are either commercially available, or may be synthesized from commercially available agents by the methods that are known to those skilled in the art. The synthesis of several representative amino acid methyl esters is illustrated in Scheme 3 and 4, which could be either saponificated into amino acid 1-1.2 by a variety of base, such as LiOH, NaOH, in the presence of protonic solvent; or reduced into aldehyde 1-1.1 by DIBAL-H.

As shown in Scheme 3, compound 3-1 containing a hydroxy group substituted at the C4-position of the pyrrolidine ring may be converted into various bicyclic amino acid methyl esters 3-6 to 3-12. Oxidation of 3-1 by a variety of oxidation agents such as ruthenium(III) chloride/NaIO₄ in wet CH₃CN may afford ketone 3-2. More reagents and conditions for the oxidation of an alcohol to a ketone can be found in Comprehensive Organic Transformations, R. C. Larock Ed., Wiley-RCH, 1999, page 1236-1249. 3-2 may then serve as a universal intermediate for further derivatization to bicyclic intermediates 3-10, 3-11 and 3-12 with different ring sizes. The allylation or homoallylation of 3-2 may be realized either by various types of nucleophilic addition, such as Grignard addition and Barbier reaction, or by electrophilic addition mediated by allylsilane or allyltin in the presence of Lewis acid. Alkene 3-4 may be converted into bicyclic 3-7 and 3-8 through iodo-etherification conditions such as I₂ and NaHCO₃ in aprotic solvent. These iodides may be further reduced to 3-11 and 3-12 under radical conditions (i.e. TMS₃SiH and AIBN) in aprotic solvent with heat. Alternatively, the homoallylation product 3-5 may be oxidatively cleaved either by ozonolysis or OsO₄/NaIO₄ to generate hemiacetal 3-9 through an aldehyde intermediate. 3-9 may be selectively reduced by a variety of reducing agents such as BH₃ or Et₃SiH optionally in the presence of Lewis acid to provide bicyclic 3-12. The double allylation product 3-3 may be converted into dihydropyrane ring 3-6 by ring closing metathesis, which may be further transformed into tetrahydropyrane ring 3-10 under various hydrogenation conditions.

Additionally as shown in Scheme 4, olefination of ketone 3-2 may be realized by various types of Wittig Reaction or Peterson Reaction, a more detailed reagents and conditions can be found in Comprehensive Organic Transformations, R. C. Larock Ed., Wiley-RCH, 1999, page 327-350. The olefin 3-2-1 may then serve as a universal intermediate for further derivatization to intermediates 3-13 to 3-19. 3-2-1 may be converted to cyclopropane 3-13 through the well-known Simmons-Smith cyclopropanation, a more detailed reagents and conditions can be found in Name Reactions and Reagents in Organic Synthesis B. P. Munday, et al Ed., Wiley, 2005, page 600 and J. C. Lorenz, et al, J. Org. Chem., 2004, 69, 327 and references cited therein. In addition, 3-2-1 may react with difluorocarbene generated from sodium chlorodifluoroacetate with heat to provide difluorocyclopropane 3-14. Also, olefin 3-2-1 may be converted into isoxazoline 3-15 by an 1,3-dipolar cycloaddition with nitrile oxide generated either from hydroxyl oxime and NCS, or from the reaction between nitroalkane and phenyl isocyanate, a more detailed reagents and conditions can be found in a review paper written by K. V. Gothelf and K. A. Jorgensen on Chem. Rev. 1998, 98, 863. Moreover, the dihydroxylation of 3-2-1 by OsO₄ and NMO may generate diol 3-16, which may be converted into amino alcohol 3-18 through nucleophilic azide substitution followed by hydrogenative azide reduction. 3-18 may then react with phosgene, triphosgene or CDI optionally in the presence of base to provide cyclic carbamate 3-19.

With a variety of suitably substituted imidazoles such as those listed in Schemes 1 and 2 in hand, the compounds of the present invention may be prepared through various coupling strategy or a combination of strategies to connect two fragments. The said strategy may include, but not limited to, Stille coupling, Suzuki coupling, Buchwald amidation, or the like.

An example of the strategies that may be used to connect the two imidazole fragments is shown in Scheme 5. Iodides 5-1, 5-3 and boronate derivative 5-2 may be prepared using procedures similar to that described previously. Iodide 5-3 may be coupled with boronate 5-2 under Suzuki condition in the presence of a Pd-catalyst to generate a core structure 5-4, which may be converted to the compounds of the present invention I-1 after selective deprotection of Boc or Cbz and installation of capping groups. Thus 5-5 may be obtained in two steps: 1) deprotection of the Boc by an acid such as HCl or TFA; and 2) the released amine functionality may be acylated with a carboxylic acid (R^(6a)COOH) under standard acylation conditions, for example a coupling reagent such as HATU or HOBt and EDC in the presence of an organic base such as DIPEA. Various carboxylic acids including amino acids in racemic or optical form are commercially available, and/or can be synthesized in racemic or optical form, see references cited in reviews by D. Seebach, et al, Synthesis, 2009, 1; C. Cativiela and M. D. Diaz-de-Villegas, Tetrahedron: Asymmetry, 2007, 18, 569; 2000, 11, 645; and 1998, 9, 3517; and experimental examples compiled in patent application WO 08/021,927A2 by C. Bachand, et al, from BMS, which is incorporated herein by reference. Compound 5-5 then may be served as a common intermediate for further derivatizations to the title compounds I-1 after a Pd-catalyzed hydrogenative deprotection and acylation with carboxylic acid R^(6b)COOH using similar procedures described above.

Alternatively, as shown in Scheme 6, the compounds of the present invention (for example I-1) may also be derived from key intermediates 6-1 and 6-2 using the Suzuki coupling procedures described previously. Both intermediates 6-1 and 6-2 have the desired acyl group already installed from 5-2 and 5-3 using similar sequences shown in Scheme 5.

The compounds of the present invention containing five-membered heteroaryl other than imidazole may be prepared using similar procedures described above in Schemes 1-6. For example, some intermediates containing a desired, suitably substituted five-membered heteroaryl have been published in US 2008/0311075A1 by C. Bachand, et al from BMS, which is incorporated by reference. These intermediates are compiled in the following table.

TABLE 10

Some intermediates and/or precursors that may be used for the synthesis of the compounds of the present invention have also been disclosed in the following patent publications: WO 2009/102568A1; WO 2009/102633A1; WO 2010/065668A1; WO 2010/065674A1; WO 2010/065681A1; WO 2010/091413A1; WO 2010/096462A1; WO 2010/096777A1; WO 2010/099527A1; US 2010/0233120A1; WO 2010/111483A1; WO 2010/111534A1; WO 2010/111673A1; WO 2010/120935A1; WO 2010/132538A1A1; WO 2010/132601A1; WO 2010/138368A1; WO 2010/138488A1; WO 2010/138790A1; WO 2010/138791A1; WO 2010/144646A2; WO 2010/148006A1; US 2010/0215618A1; WO 2011/004276A1; WO 2011/009084A2; WO 2011/015657A1; WO 2011/015658A1; WO 2011/026920A1; WO 2011/028596A1; WO 2011/031904A1; and WO 2011/031934A1, which are incorporated herein by reference in their entirety.

It will be appreciated that, with appropriate manipulation and protection of any chemical functionality, synthesis of compounds of Formula (I) is accomplished by methods analogous to those above and to those described in the Experimental section. Suitable protecting groups can be found, but are not restricted to, those found in T W Greene and P G M Wuts “Protective Groups in Organic Synthesis”, 3rd Ed (1999), J Wiley and Sons.

All references cited herein, whether in print, electronic, computer readable storage media or other form, are expressly incorporated by reference in their entirety, including but not limited to, abstracts, articles, journals, publications, texts, treatises, internet web sites, databases, patents, and patent publications.

EXAMPLES

The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.

Although the invention has been described with respect to various preferred embodiments, it is not intended to be limited thereto, but rather those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims.

Example 83

Step 83a. A solution of the compound from Example 289 below (32.0 mg, 47.0 μmol) in CH₂Cl₂ (3 mL) was treated with HCl in 1,4-dioxane (4 M, 6 mL) for 20 minutes. The volatiles were evaporated off to give the crude desired compound as a yellow solid which was directly used in the next step. ESIMS m/z=481.42 [M+H]⁺.

Step 83b. A mixture of the crude compound from step 83a (47.0 μmol at most) and (S)-(methoxycarbonyl)amino-3-methyl-butyric acid (prepared according to WO 2008/021927, 17.3 mg, 98.7 μmol) in DMF (3 mL) was treated with HATU (35.7 mg, 94.0 μmol) in the presence of DIPEA (0.12 mL, 0.940 mmol) for 1 hour at rt. The volatiles were evaporated off to provide a brown syrup, which was purified by flash column chromatography (silica, CH₂Cl₂-MeOH) to give the title compound as a light yellow solid (29.6 mg, 2 steps 79%). ESIMS m/z=795.57 [M+H]⁺.

Example 289

Step 289a. To a suspension of activated zinc powder (6.37 g, 97.5 mmol) in dry THF (100 mL) was added allyl bromide (8.5 mL, 97.4 mmol) dropwise. The resulting light yellow solution was cooled with ice-water before the 1-benzyl-2-methyl 4-oxopyrrolidine-1,2-dicarboxylate (18.0 g, 65 mmol) was added dropwise. The reaction mixture was stirred at 0° C. and warmed up to rt and kept at rt overnight before being quenched with HCl (1 N). The mixture was partitioned (EtOAc-H₂O). The organics were washed with brine, dried (Na₂SO₄) and evaporated. The residue was purified by chromatography (silica, EtOAc-hexanes) to afford the desired compound as a light yellow oil (13.66 g, 66%). ESIMS m/z=320.15 [M+H]⁺.

Step 289b. To a solution of the compound from step 289a (0.200 g, 0.627 mmol) in CH₃CN (4 mL) were added NaHCO₃ (0.211 g, 2.51 mmol) and iodine (0.477 g, 1.88 mmol). The resultant mixture were heated up to 50° C. for 4 hours before charging additional NaHCO₃ (0.211 g, 2.51 mmol) and iodine (0.477 g, 1.88 mmol). The reaction was kept at 50° C. for another 3 hours before being cooled down and quenched by aqueous Na₂S₂O₃. The volatiles were evaporated off and the residue was partitioned (EtOAc-H₂O). The organics were washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by flash column chromatography (silica, EtOAc-hexanes) to give the desired compound as a colorless oil (79.8 mg, 29%). ESIMS m/z=468.23 [M+Na]⁺.

Step 289c. Into a solution of the compound from step 289b (1.18 g, 2.66 mmol) in toluene (50 mL) were added tris(trimethylsilyl)silane (2.05 mL, 6.66 mmol) and 2,2′-azo-bis-isobutyronitrile (26.2 mg, 0.160 mmol). The resultant mixture were degassed and heated up to 90° C. under N₂ for 3 hours before being allowed to cool down and evaporated to dryness. The residue was purified by flash column chromatography (silica, EtOAc-hexanes) to give the desired compound as a colorless oil (0.333 g, 39%). ESIMS m/z=320.16 [M+H]⁺.

Step 289d. Into a solution of the compound from step 289c (0.170 g, 0.533 mmol) in MeOH (6 mL) were added palladium hydroxide (20 wt % on carbon, 50.0 mg) and Boc₂O (0.174 g, 0.799 mmol). The resulting mixture was hydrogenated under 60 psi hydrogen gas at rt for 1 day before being filtered through a plug of Celite. The filtrate was concentrated and purified by flash column chromatography (silica, EtOAc-hexanes) to give the desired compound as a colorless oil (0.127 g, 84%). ESIMS m/z=308.14 [M+Na]⁺.

Step 289e. Into a solution of the compound from step 289d (0.127 g, 0.447 mmol) in EtOH (4 mL) at 0° C. was added lithium hydroxide monohydrate (22.5 mg, 0.536 mmol) in H₂O (2 mL). The resulting mixture was gradually warmed up to rt for 1 day before being evaporated to dryness. The residue was partitioned (Et₂O—H₂O) and the aqueous phase was acidified to pH ˜2 at 0° C. The mixture was then partitioned (CH₂Cl₂—H₂O) and the organics were washed with brine, dried (Na₂SO₄), filtered and evaporated to give the crude desired compound as a colorless oil (0.122 g, 100%). ESIMS m/z=319.14 [M+Li+CH₃CN]⁺.

Step 289f. Into a solution of the crude compound from step 289e (0.224 mmol at most) in CH₃CN (4 mL) were added 2-bromo-1-(4-iodophenyl)ethanone (76.2 mg, 0.235 mmol) and DIPEA (56.0 μL, 0.447 mmol). The resultant mixture were stirred at room temperature for 1 hour before being evaporated to dryness. The residue was partitioned (EtOAc-H₂O) and the organics were washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by flash column chromatography (silica, EtOAc-hexanes) to give the desired compound as a colorless oil (98.8 mg, 2 steps 86%). ESIMS m/z=515.92 [M+H]⁺.

Step 289g. Into a solution of the crude compound from step 289f (98.8 mg, 0.192 mmol) in toluene (8 mL) was added NH₄OAc (0.296 g, 3.84 mmol). It was heated at 100° C. for 12 hours before being cooled down and evaporated to dryness. The residue was partitioned (EtOAc-H₂O) and the organics were washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by flash column chromatography (silica, EtOAc-hexanes) to give the desired compound as a light yellow oil (70.8 mg, 75%). ESIMS m/z=495.93 [M+H]⁺.

Step 289h. To a mixture of 2,4′-dibromoacetophenone (5.00 g, 18.0 mmol) and N-Boc-L-proline (3.87 g, 18.0 mmol) in CH₃CN (60 mL) was added triethylamine (5.40 mL, 37.8 mmol) slowly. The mixture was stirred at rt until the disappearance of the starting material. The volatiles were evaporated and the residue was partitioned (EtOAc-water). The organics were washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography (silica, hexanes-ethyl acetate) to give the desired compound as a light yellow foam (6.73 g, 91%). ¹H NMR (CDCl₃) 7.76 (t, J=8.0 Hz, 2H), 7.63 (dd, J=5.0, 8.5 Hz, 2H), 5.51, 5.16 (2d, J=16.0 Hz, 1H), 5.32, 5.28 (2d, J=16.5 Hz, 1H), 4.48, 4.40 (dd, J=5.0, 8.5 Hz, 1H), 3.56 (m, 1H), 3.43 (m, 1H), 2.30 (m, 2H), 2.06 (m, 1H), 1.92 (m, 1H), 1.46, 1.43 (2s, 9H).

Step 289i. To a solution of the compound from step 289h (6.73 g, 16.3 mmol) in toluene (100 mL) was added ammonium acetate (25.1 g, 0.327 mol) and the mixture was heated at 100° C. for 14 hours. The volatiles were evaporated and the residue was partitioned (EtOAc-aq. NaHCO₃). The organics were washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography (silica, hexanes-ethyl acetate) to give the desired compound as a yellow foam (6.10 g, 95%). ESIMS m/z=392.24, 394.24 [M+H]⁺. ¹H NMR (CDCl₃) 7.57 (bs, 1H), 7.48 (m, 3H), 7.23 (s, 1H), 4.97 (m, 1H), 3.42 (m, 2H), 2.99 (m, 1H), 2.16 (m, 2H), 1.97 (m, 1H), 1.46 (s, 9H).

Step 289j. To a mixture of the compound from step 289i (1.00 g, 2.55 mmol), bis(pinacolato)diboron (1.35 g, 5.33 mmol) and potassium acetate (0.640 g, 6.53 mmol) in 1,4-dioxane (20 mL) was added Pd(PPh₃)₄ (0.147 g, 0.128 mmol). The mixture was degassed and heated at 80° C. under N₂ for 14 hours. The volatiles were evaporated and the residue was partitioned (EtOAc-water). The organics were washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography (silica, hexanes-ethyl acetate) to give the desired compound as a light yellow solid (0.978 g, 87%). ESIMS m/z=440.39 [M+H]⁺. ¹H NMR (CDCl₃) 11.03, 10.55 (2s, 1H), 7.79 (m, 3H), 7.45 (m, 1H), 7.26 (m, 1H), 4.97 (m, 1H), 3.41 (m, 2H), 3.06, 2.91 (2m, 1H), 2.17 (m, 2H), 1.97 (m, 1H), 1.49 (s, 9H), 1.35 (s, 12H).

Step 289k. A mixture of the compound from step 289g (32.0 mg, 64.6 μmol), the compound from step 289j (31.2 mg, 71.0 μmol) and NaHCO₃ (21.7 mg, 0.258 mmol) in DME (9 mL) and H₂O (3 mL) was added Pd(PPh₃)₄ (7.4 mg, 6.4 μmol). The resultant mixture were degassed and heated to 95° C. under N₂ for 2 hour. The volatiles were evaporated and the residue was partitioned (EtOAc-H₂O). The organics were washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography (silica, hexanes-ethyl acetate) to give the title compound as a yellow solid (32.0 mg, 73%). ESIMS m/z=681.40 [M+H]⁺.

Example A1

Step A1a. Into a suspension of (3-bromopropyl)triphenylphosphonium bromide (16.27 g, 35 mmol) in 1,2-dimethoxylethane (150 mL) was added NaH (60%, 2.8 g, 70.0 mmol) and 2 drops of ethanol. It was stirred at 65° C. for 6.5 hours. (S)-1-(tert-butoxycarbonyl)-4-oxopyrrolidine-2-carboxylic acid (2.0 g, 8.72 mmol) was added. The mixture was further stirred 22 hours at 65° C. before being cooled to rt. Ice (10 g) was added to quench the reaction. After concentrated, the residue was partitioned (H₂O-EtOAc). The organics were separated and extracted with K₂CO₃ (1 M, 10 mL). The combined aqueous phase was cooled with ice-water and acidified with HCl (concentrated) to pH 1˜2. This cloudy mixture was extracted with EtOAc (30 mL×3). The combined organic phase was dried and concentrated to give a yellow oil (1.44 g) which was used directly in the next step.

Step A1b. A solution of the crude product from step A1a in benzene/MeOH (10 mL/10 mL) was treated with (trimethylsilyl)diazomethane (2.0 M in hexanes, 5.5 mL) until there was no more bubbling. It was concentrated and purified by chromatography (silica, EtOAc-hexanes) to afford a colorless oil (849 mg, 32% over two steps). ESIMS m/z=168.10 [M-Boc+2H]⁺.

Step A1c. Into a solution of the compound from step A1b (520 mg, 1.94 mmol) in MeOH (10 mL) was added Ruthenium (5 wt % on carbon, 50 mg). The mixture was stirred under hydrogen (60 psi) at rt for 24 hours before concentration. The residue was passed through a short plug of silica gel column to afford a light yellow oil which was used directly in the next step. ESIMS m/z=170.10 [M-Boc+2H]⁺.

Step A1d. Into a solution of the crude compound from step A1c (1.94 mmol at most) in EtOH (5 mL) and water (3 mL) was added LiOH monohydrate (98 mg, 2.33 mmol). It was stirred at rt for 3 hours and was concentrated to give a yellow oil. It was dissolved in water (10 mL), cooled in an ice/water bath and acidified to pH 1˜2 by concentrated HCl. This resulting mixture was extracted with EtOAc (20 mL×3). The combined organic phase was dried (Na₂SO₄) and concentrated to give a colorless oil (550 mg) which was used directly in the next step. ESIMS m/z=156.09 [M-Boc+2H]⁺.

Step A1e. Into a solution of the compound from step A1d (1.94 mmol at most) in acetonitrile (5 mL) and DIPEA (3 mL) was added 2-bromo-1-(4′-iodophenyl)ethanone (700 mg, 2.15 mmol). It was stirred at rt for 4 hours before concentration to a dark red oil, which was chromatographed (silica, EtOAc-hexanes) to afford the desired compound as a light yellow oil (643 mg, 66% over three steps). ESIMS m/z=400.03 [M-Boc+2H]⁺.

Step A1f. A solution of the compound from step A1e (635 mg, 1.27 mmol) in toluene (10 mL) in a sealed tube was treated with ammonium acetate (1.08 g, 14 mmol) at 105° C. overnight before being cooled and partitioned (H₂O-EtOAc). The organics were separated, dried (Na₂SO₄) and concentrated to afford a brown oil, which was chromatographed (silica, EtOAc-hexanes) to afford the desired compound as a yellow foam (504 mg, 82%). ESIMS m/z=480.04 [M+H]⁺.

Step A1g. Into the mixture of the compounds from step 289j (71 mg, 0.163 mmol) and step A1f (65 mg, 0.136 mmol) and K₂CO₃ (138 mg, 0.34 mmol) in THF (2 mL), H₂O (2 mL) was added [1,1′-Bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride (27 mg, 0.041 mmol). It was degassed and heated at 70° C. under N₂ for 4.5 hours. The volatiles were evaporated and the residue was partitioned (EtOAc-H₂O). The organic phase was washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was chromatographed (silica, CH₂Cl₂-MeOH) to give the title compound as a light yellow solid (79 mg, 81%). ESIMS m/z=665.38 [M+H]⁺.

Example A83

Step A83a. A solution of the compound from Example A1 (79 mg, 0.119 mmol) in CH₂Cl₂ (1 mL) was treated with HCl in 1,4-dioxane (4 M, 2 mL) for 1 hour. The volatiles were evaporated off to give the crude desired compound as a yellow solid which was directly used in the next step. ESIMS m/z=465.36 [M+H]⁺.

Step A83b. A mixture of the crude compound from step A83a (0.119 mmol at most) and (S)-(methoxycarbonyl)amino-3-methyl-butyric acid (prepared according to WO 2008/021927, 42 mg, 0.24 mmol) in DMF (1.5 mL) was treated with HATU (87 mg, 0.23 mmol) in the presence of DIPEA (0.5 mL) for 2 hours at rt. The volatiles were evaporated off to provide a brown syrup, which was purified by chromatography (silica, CH₂Cl₂-MeOH) to give the title compound as a light yellow solid (67 mg, 80% over 2 steps). ESIMS m/z=779.48 [M+H]⁺.

Example A229

Step A229a. Into a solution of the compound from step A1d (296 mg 1.15 mmol) in acetonitrile (6 mL) and DIPEA (2 mL) was added the 2-bromo-1-(4′-bromophenyl)-ethanone (317 mg, 1.23 mmol). It was stirred at rt for 4 hours before being concentrated to a dark red oil. It was purified by chromatography (silica, EtOAc-hexanes) to afford the desired compound as a light yellow oil (291 mg, 56%). ESIMS m/z=474.07, 476.07 [M+Na]⁺.

Step A229b. A solution of the compound from step A229a (291 mg, 0.64 mmol) in toluene (5 mL) in a sealed tube was treated with ammonium acetate (540 mg, 7.0 mmol) at 105° C. overnight before being cooled and partitioned (H₂O-EtOAc). The organic phase was separated, dried (Na₂SO₄) and concentrated to afford a brown oil, which was purified by flash column chromatography (silica, EtOAc-hexanes) to afford the desired compound as a yellow foam (225 mg, 81%). ESIMS m/z=432.01, 434.01 [M+H]⁺.

Step A229c. A solution of the compound from step A229b (225 mg, 0.52 mmol) in CH₂Cl₂ (1 mL) was treated with HCl in 1,4-dioxane (4 M, 2 mL) for 1 hour. The volatiles were evaporated off to give the crude desired compound as a yellow solid which was directly used in the next step. ESIMS m/z=332.07, 334.07 [M+H]⁺.

Step A229d. A mixture of the crude compound from step A229c (0.52 mmol at most) and (S)-(methoxycarbonyl)amino-3-methyl-butyric acid (prepared according to WO 2008/021927,101 mg, 0.57 mmol) in DMF (1.5 mL) was treated with HATU (197 mg, 0.52 mmol) in the presence of DIPEA (1.0 mL) for 2 hours at rt. The volatiles were evaporated off to provide a brown syrup, which was chromatographed (silica, EtOAc-Hexanes) to give the desired compound as a light yellow solid (214 mg, 84% 2 steps). ESIMS m/z=489.11, 491.11 [M+H]⁺.

Step A229e. Into a solution of the compound from step A229d (214 mg, 0.44 mmol) in dioxane (5 mL) was added bis(pinacolato)diboron (167 mg, 0.66 mmol), [1,1′-Bis(di-phenylphosphino)ferrocene]dichloro palladium(II) CH₂Cl₂ complex (18 mg, 0.022 mmol), KOAc (108 mg, 1.1 mmol). The resulting mixture was degassed and was heated at 85° C. for 4 hours before being cooled and partitioned (H₂O-EtOAc). The organic phase was separated, dried (Na₂SO₄) and concentrated to afford a brown oil, which was purified by chromatography (silica, EtOAc-hexanes) to afford the desired compound as a yellow foam (117 mg, 75%). ESIMS m/z=537.31 [M+H]⁺.

Step A229f. Into a solution of the compounds from steps A229d (11 mg, 0.02 mmol) and step A229e (19 mg, 0.04 mmol) and NaHCO₃ (4.5 mg, 0.056 mmol) in 1,2-dimethoxylethane (2 mL) and H₂O (1 mL) was added Pd(PPh₃)₄ (1 mg, 0.0008 mmol). The mixture were degassed and heated to 95° C. under N₂ for 3 hours. The volatiles were evaporated and the residue was partitioned (EtOAc-H₂O). The organic phase was washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography (silica, CH₂Cl₂-MeOH) to give the title compound as a light yellow solid (8 mg, 49%). ESIMS m/z=819.55 [M+H]⁺.

The title compounds of examples 1-82, 84-288, A2-A82, A84-A228 may be prepared using the chemistry described above.

TABLE 1

Examples 1-219. Entry

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

TABLE 2

Examples 220-229. Entry R R′ R″ U 220 Me H H CH₂ 221 H H H CF₂ 222 Me H H S 223 H H H

224 H Me H CH₂ 225 H H H

226 H Ph H CH₂ 227 H H H

228 H H Ph CH₂ 229 H H H

TABLE 3

Examples 230-239. Entry R R′ R″ 230 Me H H 231 H CO₂Me H 232 H CH₂OMe H 233 H H CO₂Me 234 H H CH₂OMe 235 H CH₂OH H 236 H Cl H 237 H H CH₂OH 238 H H Cl 239 Me CH₂OH H

TABLE 4

Examples 240-249. Entry R R′ R″ R′′′ 240 F H H H 241 F F H H 242 Me H H H 243 Me Me H H 244 H H Me Me 245 H H Et Et 246 CF₃ H H H 247 CF₃ H CF₃ H 248 Cl H H H 249 Cl H Cl H

TABLE 5

Examples 250-264. Entry R 250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

TABLE 6

Examples 265-270. Entry A^(a) 265

266

267

268

269

270

TABLE 7

Examples 271-276. Entry G^(g) 271

272

273

274

275

276

TABLE 8

Examples 277-288. Entry

277

278

279

280

281

282

283

284

285

286

287

288

TABLE A1

Examples Al-A219. Entry

A1 

A2 

A3 

A4 

5A 

A6 

A7 

A8 

A9 

A10 

A11 

A12 

A13 

A14 

A15 

A16 

A17 

A18 

A19 

A20 

A21 

A22 

A23 

A24 

A25 

A26 

A27 

A28 

A29 

A30 

A31 

A32 

A33 

A34 

A35 

A36 

A37 

A38 

A39 

A40 

A41 

A42 

A43 

A44 

A45 

A46 

A47 

A48 

A49 

A50 

A51 

A52 

A53 

A54 

A55 

A56 

A57 

A58 

A59 

A60 

A61 

A62 

A63 

A64 

A65 

A66 

A67 

A68 

A69 

A70 

A71 

A72 

A73 

A74 

A75 

A76 

A77 

A78 

A79 

A80 

A81 

A82 

A83 

A84 

A85 

A86 

A87 

A88 

A89 

A90 

A91 

A92 

A93 

A94 

A95 

A96 

A97 

A98 

A99 

A100

A101

A102

A103

A104

A105

A106

A107

A108

A109

A110

A111

A112

A113

A114

A115

A116

A117

A118

A119

A120

A121

A122

A123

A124

A125

A126

A127

A128

A129

A130

A131

A132

A133

A134

A135

A136

A137

A138

A139

A140

A141

A142

A143

A144

A145

A146

A147

A148

A149

A150

A151

A152

A153

A154

A155

A156

A157

A158

A159

A160

A161

A162

A163

A164

A165

A166

A167

A168

A169

A170

A171

A172

A173

A174

A175

A176

A177

A178

A179

A180

A181

A182

A183

A184

A185

A186

A187

A188

A189

A190

A191

A192

A193

A194

A195

A196

A197

A198

A199

A200

A201

A202

A203

A204

A205

A206

A207

A208

A209

A210

A211

A212

A213

A214

A215

A216

A217

A218

A219

TABLE A2

Examples A220-A229. Entry R R′ R″ U A220 Me H H CH₂ A221 H H H CF₂ A222 Me H H S A223 H H H

A224 H Me H CH₂ A225 H H H

A226 H Ph H CH₂ A227 H H H

A228 H H Ph CH₂ A229 H H H

TABLE A3

Examples A230-A239. Entry R R′ R″ A230 Me H H A231 H CO₂Me H A232 H CH₂OMe H A233 H H CO₂Me A234 H H CH₂OMe A235 H CH₂OH H A236 H Cl H A237 H H CH₂OH A238 H H Cl A239 Me CH₂OH H

TABLE A4

Examples A240-A249. Entry R R′ R″ R′′′ A240 F H H H A241 F F H H A242 Me H H H A243 Me Me H H A244 H H Me Me A245 H H Et Et A246 CF₃ H H H A247 CF₃ H CF₃ H A248 Cl H H H A249 Cl H Cl H

TABLE A5

Examples A250-A276. Entry R A250

A251

A252

A253

A254

A255

A256

A257

A258

A259

A260

A261

A262

A263

A264

A265

A266

A267

A268

A269

A270

A271

A272

A273

A274

A275

A276

TABLE A6

Examples A277-A282. Entry A^(a) A277

A278

A279

A280

A281

A282

TABLE A7

Examples A283-A288. Entry G^(g) A283

A284

A285

A286

A287

A288

TABLE A8

Examples A289-A297. Entry L^(a) L^(b) A289

H A290 H

A291 H CO₂Me A292

H A293 H

A294 CO₂Me H A295

H A296 H

A297

H Biological Activity 1. HCV Replicon Cell Lines

HCV replicon cell lines (kindly provided by R. Bartenschlager) isolated from colonies as described by Lohman et al. (Lohman et al. (1999) Science 285: 110-113, expressly incorporated by reference in its entirety) and used for all experiments. The HCV replicon has the nucleic acid sequence set forth in EMBL Accession No.: AJ242651, the coding sequence of which is from nucleotides 1801 to 8406.

The coding sequence of the published HCV replicon was synthesized and subsequently assembled in a modified plasmid pBR322 (Promega, Madison, Wis.) using standard molecular biology techniques. One replicon cell line (“SGR 11-7”) stably expresses HCV replicon RNA which consists of: (i) the HCV 5′UTR fused to the first 12 amino acids of the capsid protein, (ii) the neomycin phosphotransferase gene (neo), (iii) the IRES from encephalomyocarditis virus (EMCV), and (iv) HCV NS2 to NS5B genes and the HCV 3′UTR. Another replicon cell line (“Huh-luc/neo-ET”) described by Vrolijk et al. (Vrolijk et. al. (2003) Journal of Virological Methods 110:201-209, expressly incorporated by reference in its entirety) stably expresses HCV replicon RNA which consists of (i) the HCV 5′UTR fused to the first 12 amino acids of the capsid protein, (ii) the firefly luciferase reporter gene, (iii) the ubiquitin gene, (iv) the neomycin phosphotransferase gene (neo), (v) the IRES from encephalomyocarditis virus (EMCV) and (vi) HCV NS3 to NS5B genes that harbor cell culture adaptive mutations (E1202G, T1280I, K1846T) and the HCV 3′UTR.

These cell lines are maintained at 37° C., 5% CO₂, 100% relative humidity in DMEM (Cat #11965-084, Invitrogen), with 10% fetal calf serum (“FCS”, Invitrogen), 1% non-essential amino acids (Invitrogen), 1% of Glutamax (Invitrogen), 1% of 100× penicillin/streptomycin (Cat #15140-122, Invitrogen) and Geneticin (Cat #10131-027, Invitrogen) at 0.75 mg/ml or 0.5 mg/ml for 11-7 and Huh-luc/neo-ET cells, respectively.

2. HCV Replicon Assay—qRT-PCR

EC₅₀ values of single agent compounds were determined by HCV RNA detection using quantitative RT-PCR, according to the manufacturer's instructions, with a TAQMAN® One-Step RT-PCR Master Mix Reagents Kit (Cat #AB 4309169, Applied Biosystems) on an ABI Model 7500 thermocycler. EC₅₀ values of combinations are similarly determined by HCV RNA detection using quantitative RT-PCR. The TAQMAN primers to use for detecting and quantifying HCV RNA obtained from Integrated DNA Technologies. HCV RNA is normalized to GAPDH RNA levels in drug-treated cells, which is detected and quantified using the Human GAPDH Endogenous Control Mix (Applied Biosystems, AB 4310884E). Total cellular RNA is purified from 96-well plates using the RNAqueous 96 kit (Ambion, Cat #AM1812). Chemical agent cytotoxicity is evaluated using an MTS assay according to the manufacturer's directions (Promega).

3. HCV Replicon Assay—Luciferase

Since clinical drug resistance often develops in viral infections following single agent therapies, there is a need to assess the additive, antagonistic, or synergistic properties of combination therapies. We use the HCV replicon system to assess the potential use of the compounds of the present invention or in combination therapies with Interferon alpha, cyclosporine analogs and inhibitors targeting other HCV proteins. The acute effects of a single or combinations of drugs are studied in the “Huh-luc/neo-ET” replicon with each chemical agent titrated in an X or Y direction in a 6 point two-fold dilution curve centered around the EC50 of each drug. Briefly, replicon cells are seeded at 7,000 cells per well in 90 ul DMEM (without phenol red, Invitrogen Cat. #31053-036) per well with 10% FCS, 1% non-essential amino acids, 1% of Glutamax and 1% of 100× penicillin/streptomycin and incubated overnight at 37° C., 5% CO₂, 100% relative humidity. 16-20 h after seeding cells, test compounds previously solubilized and titrated in dimethyl sulfoxide (“DMSO”) from each X plate and Y plate are diluted 1:100 in DMEM (without phenol red, Invitrogen Cat. #31053-036) with 10% FCS, 1% non-essential amino acids, 1% of Glutamax and 1% of 100× penicillin/streptomycin and added directly to the 96-well plate containing cells and growth medium at a 1:10 dilution for a final dilution of compound and DMSO of 1:1000 (0.2% DMSO final concentration). Drug treated cells are incubated at 37° C., 5% CO₂, 100% relative humidity for 72 hours before performing a luciferase assay using 100 ul per well BriteLite Plus (Perkin Elmer) according to the manufacturer's instructions. Data analysis utilizes the method published by Prichard and Shipman (Antiviral Research, 1990. 14:181-205). Using this method, the combination data are analyzed for antagonistic, additive, or synergistic combination effects across the entire combination surface created by the diluted compounds in combination.

The compounds of the present invention may inhibit HCV by mechanisms in addition to or other than NS5A inhibition. In one embodiment the compounds of the present invention inhibit HCV replicon and in another embodiment the compounds of the present invention inhibit NS5A.

The compounds of the present invention can be effective against the HCV 1b genotype. It should also be understood that the compounds of the present invention can inhibit multiple genotypes of HCV. In one embodiment compound of the present invention are active against the 1a, 1b, 2a, 2b, 3a, 4a, and 5a genotypes. Table 11 shows the EC₅₀ values of representative compounds of the present invention against the HCV 1a or 1b genotype from the above described qRT-PCR assay.

TABLE 11 Genotype-1a or 1b replicon EC₅₀ Example 1b EC₅₀ Example 1a EC₅₀ Example 1b EC₅₀ 83 19 pM A83 70 pM A229 87 pM

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. 

What is claimed:
 1. A compound represented by Formula (I):

or a pharmaceutically acceptable salt thereof, wherein: Ring A and ring B are each independently optionally substituted phenyl or optionally substituted 6-membered heteroaryl containing one or more nitrogen atoms; Ring G and ring W are each independently optionally substituted 5-membered heteroaryl containing one or more nitrogen atoms; L¹ and L² are taken together with the carbon atom to which they are attached to form a group selected from:

R^(x) is hydrogen or C₁-C₄ alkyl; Y at each occurrence is independently C(O) or S(O)₂; R¹ at each occurrence is hydrogen or optionally substituted C₁-C₄ alkyl; R³ and R⁴ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, and optionally substituted C₃-C₈ cycloalkyl; alternatively, R³ and R⁴ can be taken together with the carbon atom to which they are attached to form optionally substituted C₃-C₈ cycloalkyl or optionally substituted heterocyclic; R⁵ is hydrogen, optionally substituted C₁-C₈ alkyl, or optionally substituted C₃-C₈ cycloalkyl; alternatively R³, R⁴ and R⁵ are taken together with the carbon atom and nitrogen atom to which they are attached to form

U is absent or independently selected from O, S, S(O), SO₂, NC(O)—(C₁-C₄ alkyl), C(O), protected carbonyl, OCH₂, OCH₂CH₂, SCH₂, SCH₂CH₂, C(R⁷)₂, and C(R⁷)₂C(R⁷)₂; R⁷ at each occurrence is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl), amino optionally substituted with one or two C₁-C₄ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₃-C₇ cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted C₁-C₄ alkyl; alternatively two geminal R⁷ groups are taken together with the carbon atom to which they are attached to form a spiro, optionally substituted 3- to 7-membered ring selected from the group consisting of C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl and 3- to 7-membered heterocyclic, each optionally substituted; R^(7a) and R^(7b) at each occurrence are each independently selected from the group consisting of hydrogen, optionally substituted aryl, and optionally substituted C₁-C₄ alkyl; Alternatively, CHR^(7a)—U or CHR^(7b)—U are taken together to form a group selected from CH═CH, fused and optionally substituted C₃-C₈ cycloalkyl, fused and optionally substituted aryl, or fused and optionally substituted heterocyclic; yet alternatively, U, R^(7a), and R^(7b) are taken together with the carbon atoms to which they are attached to form a bridged, optionally substituted 4- to 7-membered ring selected from the group consisting of C₄-C₇ cycloalkyl, C₄-C₇ cycloalkenyl and 4- to 7-membered heterocyclic, each optionally substituted; and R⁶ at each occurrence is independently selected from the group consisting of O(C₁-C₈ alkyl), amino, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, heterocyclic, aryl, and heteroaryl, each optionally substituted.
 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof; wherein both ring A and ring B are each independently optionally substituted phenyl.
 3. A compound represented by Formula (I):

or a pharmaceutically acceptable salt thereof; wherein L¹ is —C(O)₂CH₃ and L² is hydrogen; Ring A and ring B are optionally substituted phenyl; Ring G and ring W are each independently optionally substituted 5-membered heteroaryl containing one or more nitrogen atoms; Y at each occurrence is independently C(O) or S(O)₂; R¹ at each occurrence is hydrogen or optionally substituted C₁-C₄ alkyl; R³ and R⁴ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, and optionally substituted C₃-C₈ cycloalkyl; alternatively, R³ and R⁴ can be taken together with the carbon atom to which they are attached to form optionally substituted C₃-C₈ cycloalkyl or optionally substituted heterocyclic; R⁵ is hydrogen, optionally substituted C₁-C₈ alkyl, or optionally substituted C₃-C₈ cycloalkyl; alternatively R³, R⁴ and R⁵ are taken together with the carbon atom and nitrogen atom to which they are attached to form

U is absent or independently selected from O, S, S(O), SO₂, NC(O)—(C₁-C₄ alkyl), C(O), protected carbonyl, OCH₂, OCH₂CH₂, SCH₂, SCH₂CH₂, C(R⁷)₂, and C(R⁷)₂C(R⁷)₂; R⁷ at each occurrence is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl), amino optionally substituted with one or two C₁-C₄ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₃-C₇ cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted C₁-C₄ alkyl; alternatively two geminal R⁷ groups are taken together with the carbon atom to which they are attached to form a spiro, optionally substituted 3- to 7-membered ring selected from the group consisting of C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl and 3- to 7-membered heterocyclic, each optionally substituted; R^(7a) and R^(7b) at each occurrence are each independently selected from the group consisting of hydrogen, optionally substituted aryl, and optionally substituted C₁-C₄ alkyl; alternatively, CHR^(7a)—U or CHR^(7b)—U are taken together to form a group selected from CH═CH, fused and optionally substituted C₃-C₈ cycloalkyl, fused and optionally substituted aryl, or fused and optionally substituted heterocyclic; yet alternatively, U, R^(7a), and R^(7b) are taken together with the carbon atoms to which they are attached to form a bridged, optionally substituted 4- to 7-membered ring selected from the group consisting of C₄-C₇ cycloalkyl, C₄-C₇ cycloalkenyl and 4- to 7-membered heterocyclic, each optionally substituted; and R⁶ at each occurrence is independently selected from the group consisting of O(C₁-C₈ alkyl), amino, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, heterocyclic, aryl, and heteroaryl, each optionally substituted.
 4. The compound of claim 1, or a pharmaceutically acceptable salt thereof wherein ring G and ring W are each independently illustrated by one of the following heteroaryl groups:

wherein each of the above shown heteroaryl groups is optionally substituted.
 5. The compound of claim 1, represented by Formula (Ia), or (Ib):

or a pharmaceutically acceptable salt thereof.
 6. A compound represented by Formula (Ia), or (Ib):

or a pharmaceutically acceptable salt thereof; wherein R¹ is hydrogen; and R⁶ is optionally substituted C₁-C₈ alkyl; L¹ is optionally substituted 5- to 7-membered heteroaryl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₃-C₇ cycloalkenyl, or optionally substituted 3- to 7-membered heterocyclic; and L² is hydrogen; R³ and R⁴ are each independently selected from the group consisting of hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, and optionally substituted C₃-C₈ cycloalkyl; alternatively, R³ and R⁴ can be taken together with the carbon atom to which they are attached to form optionally substituted C₃-C₈ cycloalkyl or optionally substituted heterocyclic; R⁵ is hydrogen, optionally substituted C₁-C₈ alkyl, or optionally substituted C₃-C₈ cycloalkyl; U is independently selected from O, S, S(O), SO₂, NC(O)—(C₁-C₄ alkyl), C(O), protected carbonyl, OCH₂, OCH₂CH₂, SCH₂, SCH₂CH₂, C(R⁷)₂, and C(R⁷)₂C(R⁷)₂; R⁷ at each occurrence is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl), amino optionally substituted with one or two C₁-C₄ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted C₃-C₇ cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted C₁-C₄ alkyl; alternatively two geminal R⁷ groups are taken together with the carbon atom to which they are attached to form a spiro, optionally substituted 3- to 7-membered ring selected from the group consisting of C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl and 3- to 7-membered heterocyclic, each optionally substituted; R^(7a) and R^(7b) at each occurrence are each independently selected from the group consisting of hydrogen, optionally substituted aryl, and optionally substituted C₁-C₄ alkyl; alternatively, CHR^(7a)—U or CHR^(7b)—U are taken together to form a group selected from CH═CH, fused and optionally substituted C₃-C₈ cycloalkyl, fused and optionally substituted aryl, or fused and optionally substituted heterocyclic; alternatively, U, R^(7a), and R^(7b) are taken together with the carbon atoms to which they are attached to form a bridged, optionally substituted 4- to 7-membered ring selected from the group consisting of C₄-C₇ cycloalkyl, C₄-C₇ cycloalkenyl and 4- to 7-membered heterocyclic, each optionally substituted.
 7. The compound of claim 5, wherein R⁶ is C₁-C₈ alkyl optionally substituted with amino, cyano, halogen, hydroxy, protected amino, aryl, heteroaryl or O(C₁-C₄ alkyl).
 8. The compound of claim 1, or a pharmaceutically acceptable salt thereof; wherein

is selected from:


9. A compound selected from the group of compounds 1-288 compiled in the following tables: Compounds 1-219

Entry

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

Compounds 220-229

Entry R R′ R″ U 220 Me H H CH₂ 221 H H H CF₂ 222 Me H H S 223 H H H

224 H Me H CH₂ 225 H H H

226 H Ph H CH₂ 227 H H H

228 H H Ph CH₂ 229 H H H

Compounds 230-239

Entry R R′ R″ 230 Me H H 231 H CO₂Me H 232 H CH₂OMe H 233 H H CO₂Me 234 H H CH₂OMe 235 H CH₂OH H 236 H Cl H 237 H H CH₂OH 238 H H Cl 239 Me CH₂OH H

Compounds 240-249

Entry R R′ R″ R′′′ 240 F H H H 241 F F H H 242 Me H H H 243 Me Me H H 244 H H Me Me 245 H H Et Et 246 CF₃ H H H 247 CF₃ H CF₃ H 248 Cl H H H 249 Cl H Cl H

Compounds 250-264

Entry R 250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Compounds 265-270

Entry A^(a) 265

266

267

268

269

270

Compounds 271-276

Entry G^(g) 271

272

273

274

275

276

Compounds 277-288

Entry

277

280

281

282

283

284

286

287

288


10. A pharmaceutical composition comprising a compound or a combination of compounds according to claim 1 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.
 11. A method of inhibiting the replication of an RNA-containing virus comprising contacting said virus with a therapeutically effective amount of a compound or combination of compounds of claim 1, or a pharmaceutically acceptable salt thereof wherein said RNA-containing virus is hepatitis C virus.
 12. A method of treating infection caused by an RNA-containing virus comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or combination of compounds of claim 1, or a pharmaceutically acceptable salt thereof wherein said RNA-containing virus is hepatitis C virus.
 13. The method of claim 12, further comprising the step of co-administering one or more agents selected from the group consisting of a host immune modulator and an antiviral agent, or a combination thereof.
 14. The method of claim 13, wherein the host immune modulator is selected from the group consisting of interferon-alpha, pegylated-interferon-alpha, interferon-beta, interferon-gamma, consensus interferon, a cytokine, and a vaccine.
 15. The method of claim 13, wherein the antiviral agents inhibit replication of HCV by inhibiting host cellular functions associated with viral replication.
 16. The method of claim 13, wherein the antiviral agents inhibit the replication of HCV by targeting proteins of the viral genome.
 17. The method of claim 13, wherein said antiviral agent is an inhibitor of a HCV viral protein, a replication process or a combination thereof, wherein said targeting protein or replication process is selected from the group consisting of helicase, protease, polymerase, metalloprotease, NS4A, NS4B, NS5A, assembly, entry, and IRES.
 18. The method of claim 12, further comprising the step of co-administering an agent or combination of agents that treat or alleviate symptoms of HCV infection selected from cirrhosis and inflammation of the liver.
 19. The method of claim 12, further comprising the step of co-administering one or more agents that treat patients for disease caused by hepatitis B (HBV) infection.
 20. The method of claim 12, further comprising the step of co-administering one or more agents that treat patients for disease caused by human immunodeficiency virus (HIV) infection.
 21. The pharmaceutical composition of claim 10, further comprising an agent selected from interferon, pegylated interferon, ribavirin, amantadine, an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, or an internal ribosome entry site inhibitor.
 22. The composition of claim 10, further comprising a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof.
 23. The composition of claim 22, wherein the cytochrome P450 monooxygenase inhibitor is ritonavir.
 24. A method of treating hepatitis C infection in a subject in need thereof comprising co-administering to said subject a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof, and a compound of claim 1 or a pharmaceutically acceptable salt thereof.
 25. A process of making a compound according to claim 1 comprising: i) preparing a compound of Formula (I-a):

via a transition-metal catalyzed cross-coupling reaction, wherein: Z^(a) and Z^(b) are each independently an amino protecting group or —C(O)—R⁶; wherein R⁶ is C₁-C₈ alkyl optionally substituted with amino, hydroxy, protected amino, or O(C₁-C₄ alkyl); and ring A, ring B, ring G, ring W, U, L¹, L², R¹, R³, R⁴, R⁵, R^(7a) and R^(7b) are as defined in claim 1; ii) When Z^(a) or Z^(b) is an amino protecting group, fully or selectively deprotecting a compound of Formula (I-a) to give the corresponding amine of Formula (I-b):

wherein Z^(c) is hydrogen, an amino protecting group or —C(O)—R⁶; iii) Capping the released amino group of a compound of Formula (I-b) with LG-C(O)—R⁶, wherein LG is a leaving group; to give the compound of Formula (I-c):

wherein Z^(d) is an amino protecting group or —C(O)—R⁶; and iv) when Z^(d) is an amino protecting group, repeated reaction sequence of deprotecting and capping (step ii-iii) to give the compound of Formula (I-d):


26. A compound selected from the group of compounds A1-A297 compiled in the following tables: Compounds A1-A219

Entry

A1

A2

A3

A4

5A

A6

A7

A8

A9

A10

A11

A12

A13

A14

A15

A16

A17

A18

A19

A20

A21

A22

A23

A24

A25

A26

A27

A28

A29

A30

A31

A32

A33

A34

A35

A36

A37

A38

A39

A40

A41

A42

A43

A44

A45

A46

A47

A48

A49

A50

A51

A52

A53

A54

A55

A56

A57

A58

A59

A60

A61

A62

A63

A64

A65

A66

A67

A68

A69

A70

A71

A72

A73

A74

A75

A76

A77

A78

A79

A80

A81

A82

A83

A84

A85

A86

A87

A88

A89

A90

A91

A92

A93

A94

A95

A96

A97

A98

A99

A100

A101

A102

A103

A104

A105

A106

A107

A108

A109

A110

A111

A112

A113

A114

A115

A116

A117

A118

A119

A120

A121

A122

A123

A124

A125

A126

A127

A128

A129

A130

A131

A132

A133

A134

A135

A136

A137

A138

A139

A140

A141

A142

A143

A144

A145

A146

A147

A148

A149

A150

A151

A152

A153

A154

A155

A156

A157

A158

A159

A160

A161

A162

A163

A164

A165

A166

A167

A168

A169

A170

A171

A172

A173

A174

A175

A176

A177

A178

A179

A180

A181

A182

A183

A184

A185

A186

A187

A188

A189

A190

A191

A192

A193

A194

A195

A196

A197

A198

A199

A200

A201

A202

A203

A204

A205

A206

A207

A208

A209

A210

A211

A212

A213

A214

A215

A216

A217

A218

A219

Compounds A220-A229

Entry R R′ R″ U A220 Me H H CH₂ A221 H H H CF₂ A222 Me H H S A223 H H H

A224 H Me H CH₂ A225 H H H

A226 H Ph H CH₂ A227 H H H

A228 H H Ph CH₂ A229 H H H

Compounds A230-A239

Entry R R′ R″ A230 Me H H A231 H CO₂Me H A232 H CH₂OMe H A233 H H CO₂Me A234 H H CH₂OMe A235 H CH₂OH H A236 H Cl H A237 H H CH₂OH A238 H H Cl A239 Me CH₂OH H

Compounds A240-A249

Entry R R′ R″ R′′′ A240 F H H H A241 F F H H A242 Me H H H A243 Me Me H H A244 H H Me Me A245 H H Et Et A246 CF₃ H H H A247 CF₃ H CF₃ H A248 Cl H H H A249 Cl H Cl H

Compounds A250-A276

Entry R A250

A251

A252

A253

A254

A255

A256

A257

A258

A259

A260

A261

A262

A263

A264

A265

A266

A267

A268

A269

A270

A271

A272

A273

A274

A275

A276

Compounds A277-A282

Entry A^(a) A277

A278

A279

A280

A281

A282

Compounds A283-A288

Entry G^(g) A283

A284

A285

A286

A287

A288

Compounds A289-A297

Entry L^(a) L^(b) A289

H A290 H

A291 H CO₂Me A292

H A293 H

A294 CO₂Me H A295

H A296 H

A297

H. 